<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bone Joint Surg Am</journal-id><journal-id journal-id-type="iso-abbrev">J Bone Joint Surg Am</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">jbjsam</journal-id><journal-title-group><journal-title>The Journal of Bone and Joint Surgery. American Volume</journal-title></journal-title-group><issn pub-type="ppub">0021-9355</issn><issn pub-type="epub">1535-1386</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430733</article-id><article-id pub-id-type="pmcid-ver">PMC12430733.1</article-id><article-id pub-id-type="pmcaid">12430733</article-id><article-id pub-id-type="pmcaiid">12430733</article-id><article-id pub-id-type="pmid">40729448</article-id><article-id pub-id-type="doi">10.2106/JBJS.24.01205</article-id><article-id pub-id-type="publisher-id">JBJS-D-24-01205</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>0150</subject></subj-group><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Osteobiologics for Lumbar Spinal Fusion</article-title><subtitle>A Systematic Review and Network Meta-Analysis</subtitle></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2424-1274</contrib-id><name name-style="western"><surname>Ambrosio</surname><given-names initials="L">Luca</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><email>luc.ambros@gmail.com</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5489-2591</contrib-id><name name-style="western"><surname>Schol</surname><given-names initials="J">Jordy</given-names></name><degrees>MSc</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><email>bb.jordy@gmail.com</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5384-8158</contrib-id><name name-style="western"><surname>Tamagawa</surname><given-names initials="S">Shota</given-names></name><degrees>MD, PhD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><email>s-tamagawa@juntendo.ac.jp</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7143-4354</contrib-id><name name-style="western"><surname>Muthu</surname><given-names initials="S">Sathish</given-names></name><degrees>MD, PhD</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><email>drsathishmuthu@gmail.com</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4189-9270</contrib-id><name name-style="western"><surname>Sakai</surname><given-names initials="D">Daisuke</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><email>daisakai@is.icc.u-tokai.ac.jp</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6069-4871</contrib-id><name name-style="western"><surname>Papalia</surname><given-names initials="R">Rocco</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><email>r.papalia@policlinicocampus.it</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7142-1660</contrib-id><name name-style="western"><surname>Vadal&#224;</surname><given-names initials="G">Gianluca</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4739-9795</contrib-id><name name-style="western"><surname>Denaro</surname><given-names initials="V">Vincenzo</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><email>denaro@policlinicocampus.it</email></contrib><aff id="aff1"><label>1</label>Research Unit of Orthopaedic and Trauma Surgery, Faculty of Medicine and Surgery, Universit&#224; Campus Bio-Medico Di Roma, Rome, <country>Italy</country></aff><aff id="aff2"><label>2</label>Operative Research Unit of Orthopaedic and Trauma Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, <country>Italy</country></aff><aff id="aff3"><label>3</label>Department of Orthopedic Surgery, Tokai University School of Medicine, Isehara, <country>Japan</country></aff><aff id="aff4"><label>4</label>Center for Musculoskeletal Innovative Research and Advancement (C-MiRA), Tokai University Graduate School, Isehara, <country>Japan</country></aff><aff id="aff5"><label>5</label>Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, <country>Japan</country></aff><aff id="aff6"><label>6</label>Department of Orthopaedics, Government Medical College, Karur, <country>India</country></aff><aff id="aff7"><label>7</label>Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore, <country>India</country></aff><aff id="aff8"><label>8</label>Department of Spine Surgery, Orthopaedic Research Group, Coimbatore, <country>India</country></aff></contrib-group><author-notes><corresp id="cor1"><label>a</label>Email for corresponding author: <email>g.vadala@policlinicocampus.it</email></corresp></author-notes><pub-date pub-type="ppub"><day>17</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2025</year></pub-date><volume>107</volume><issue>18</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>2110</fpage><lpage>2121</lpage><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by The Journal of Bone and Joint Surgery, Incorporated.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jbjsam-107-2110.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jbjsam-107-2110.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" ext-link-type="doi" xlink:href="10.2106/JBJS.25.00440"><pub-id pub-id-type="doi">10.2106/JBJS.25.00440</pub-id></related-article><abstract><sec><title>Background:</title><p>Lumbar spinal fusion (LSF) is a common surgical procedure for treating lumbar degenerative conditions. The use of osteobiologics to enhance fusion has emerged as a promising alternative to address the limitations of autologous iliac crest bone graft (AICBG), but their comparative efficacy and safety remain unclear. This systematic review and network meta-analysis (NMA) aimed to assess the fusion rates, safety profiles, and clinical outcomes of the use of osteobiologics in LSF.</p></sec><sec><title>Methods:</title><p>PubMed/MEDLINE and Scopus databases were searched for randomized controlled trials (RCTs) comparing different osteobiologics to AICBG in LSF. Data on fusion rates, complications, pain, disability, blood loss, operative time, and length of stay (LOS) were extracted. The risk of bias was evaluated using the Cochrane Risk of Bias-2 tool, and the certainty of evidence was assessed using the GRADE framework. The NMA was performed using a frequentist random-effects model to compare the efficacy and safety of various osteobiologics, along with associated perioperative and clinical outcomes.</p></sec><sec><title>Results:</title><p>Forty-three RCTs including a total of 3,823 patients were identified. The use of rhBMP-2 (recombinant human bone morphogenetic protein-2) significantly improved fusion rates (odds ratio [OR]: 3.71; 95% confidence interval [CI]: 2.59 to 5.32; p &lt; 0.0001) and reduced complications (OR: 0.30; 95% CI: 0.13 to 0.68; p &lt; 0.0001) compared with AICBG, with moderate certainty of the evidence. Other osteobiologics, including ABM/P-15 (anorganic bone matrix/15-amino acid peptide fragment) and allograft, demonstrated reduced complication rates, although the quality of the evidence was low to very low. No significant differences were observed for pain, disability, or LOS. The use of rhBMP-2, autologous local bone, and silicate-substituted calcium phosphate was associated with decreased operative time, with rhBMP-2 additionally associated with lower intraoperative blood loss.</p></sec><sec><title>Conclusions:</title><p>Use of rhBMP-2 was associated with significantly higher fusion and lower complication rates compared with AICBG, as well as decreased operative time and blood loss. Other osteobiologics may also offer benefits, but the supporting evidence is low-quality and limited by the notable underrepresentation of these materials in the published literature.</p></sec><sec><title>Level of Evidence:</title><p>Therapeutic <underline>Level I</underline>. See Instructions for Authors for a complete description of levels of evidence.</p></sec></abstract><counts><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Lumbar spinal fusion (LSF) is a widely employed surgical technique for treating degenerative conditions of the lumbar spine<sup><xref rid="bib1" ref-type="bibr">1</xref></sup>. Achieving successful spinal fusion poses numerous challenges, including the risk of pseudarthrosis, which occurs in an estimated 5% to 15% of cases<sup><xref rid="bib2" ref-type="bibr">2</xref></sup>. The lack of osseous fusion can result in persistent pain, spinal instability, and hardware loosening or breakage, with increased risks of revision surgery, adjacent segment disease, and considerable socioeconomic burdens<sup><xref rid="bib3" ref-type="bibr">3</xref></sup>.</p><p>Successful fusion depends on the stabilizing effect of spinal instrumentation and the use of osteobiologics to enhance bone healing<sup><xref rid="bib4" ref-type="bibr">4</xref></sup>. These materials include various grafts and other materials with diverse osteoinductive, osteoconductive, and osteogenic properties, which contribute to new bone growth at the fusion site<sup><xref rid="bib5" ref-type="bibr">5</xref></sup>. Traditionally, autologous iliac crest bone graft (AICBG) has been considered the gold standard in LSF, due to its inherent osteoconductive and osteoinductive properties coupled with its prompt availability. Despite its effectiveness, the use of AICBG is limited by donor-site morbidity and restricted availability<sup><xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib6" ref-type="bibr">6</xref></sup>. Additionally, the large market potential of osteobiologics (&gt;$9 billion in 2024<sup><xref rid="bib7" ref-type="bibr">7</xref></sup>) has spurred the development of alternative products designed to mimic or surpass the fusion capabilities of AICBG while minimizing adverse events.</p><p>Over the years, numerous osteobiologics, including allografts, recombinant human bone morphogenetic proteins (rhBMPs), cell-based or cell-derived products, and synthetic materials, have been explored for their potential to enhance spinal fusion<sup><xref rid="bib8" ref-type="bibr">8</xref>-<xref rid="bib12" ref-type="bibr">12</xref></sup>. These alternatives vary remarkably in their biological activity, clinical efficacy, cost, and safety profiles<sup><xref rid="bib13" ref-type="bibr">13</xref></sup>. To date, the safety and efficacy of available osteobiologics have been widely assessed in multiple randomized controlled trials (RCTs). While reporting generally favorable outcomes with most grafts, previous meta-analyses have highlighted notable limitations, such as small sample sizes and low quality among the included studies<sup><xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref></sup>.</p><p>We conducted this systematic review and network meta-analysis (NMA) of RCTs to evaluate fusion rates, safety profiles, and clinical outcomes associated with the use of osteobiologics in LSF. Our objective was to establish a comparative framework to rank these products and their combinations, providing insights into the most effective and safest options for promoting solid fusion.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><p>This systematic review was performed following PRISMA (Preferred Items for Systematic Reviews and Meta-Analyses) guidelines<sup><xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref></sup>. The review protocol was registered in the PROSPERO database (CRD42024514566). Complete details regarding the methodology utilized for this study are available in the Appendix eMethods section.</p><sec><title>Electronic Literature Search</title><p>A systematic search of PubMed/MEDLINE and Scopus databases was performed for literature published up to March 1, 2024. We searched for studies including adult patients affected by lumbar degenerative disorders who underwent LSF augmented with osteobiologics (see Appendix eSupplement 1). Primary outcomes included fusion at the surgically treated segment(s) and osteobiologic-related complications (see Appendix eSupplement 2)<sup><xref rid="bib8" ref-type="bibr">8</xref></sup>. Secondary outcomes included patient-reported outcome measures (PROMs) of pain and disability as well as perioperative outcomes.</p></sec><sec><title>Study Selection</title><p>Article screening and duplicate detection was performed using the Rayyan platform. Three reviewers (L.A., J.S., and S.T.) independently screened the titles and abstracts of the identified studies. Articles with consensus from at least 2 reviewers advanced to full-text screening. In case of disagreement, the reviewers discussed the inconsistencies until a unanimous decision was reached.</p></sec><sec><title>Data Extraction</title><p>Extracted data included the study characteristics, patient demographics, diagnoses, types of surgery, osteobiologics employed, and use of postoperative lumbar orthoses. A complete list of the definitions of radiographic fusion reported in the included studies is available in Appendix eTable 1. Perioperative outcomes included complications, blood loss, operative time, and length of stay (LOS). Additionally, PROMs of disability (Oswestry Disability Index [ODI]) and low back pain (LBP) severity (on a numeric rating scale [NRS] or visual analogue scale [VAS]) were extracted.</p></sec><sec><title>Risk of Bias and Certainty of the Evidence</title><p>The Cochrane Risk of Bias (RoB)-2 tool<sup><xref rid="bib17" ref-type="bibr">17</xref></sup> was utilized to assess the quality of the included studies, and the certainty of the evidence was assessed with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework<sup><xref rid="bib18" ref-type="bibr">18</xref></sup>.</p></sec><sec><title>Statistical Analysis</title><p>Odds ratios (ORs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes were calculated with 95% confidence intervals (CIs). Pairwise comparisons were made, and NMA was performed using a frequentist approach<sup><xref rid="bib19" ref-type="bibr">19</xref></sup> and random-effect models. As the gold standard in LSF, AICBG was selected as the reference treatment. For each primary outcome, the treatments were ranked using the surface under the cumulative ranking curve (SUCRA)<sup><xref rid="bib20" ref-type="bibr">20</xref></sup>. For the fusion and complication outcomes, subgroup NMAs were also performed to compare included studies according to funding status. The netmeta package within RStudio (Posit) was used to perform the analyses.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Study Selection</title><p>A total of 5,834 articles were identified from the database search, 4,133 remained following duplicate removal, and 4,069 were excluded after title and abstract screening. Subsequently, 64 full-text articles were sought for retrieval; 2 were not found. The remaining 62 full-text articles were screened and 19 were excluded. The remaining 43 articles were included in the review (Fig. <xref rid="fig1" ref-type="fig">1</xref>).</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>Fig. 1</label><caption><p>PRISMA flowchart depicting the article screening process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jbjsam-107-2110-g001.jpg"/></fig></sec><sec><title>Study Characteristics</title><p>The 43 RCTs (42 two-arm<sup><xref rid="bib21" ref-type="bibr">21</xref>-<xref rid="bib62" ref-type="bibr">62</xref></sup> and 1 three-arm<sup><xref rid="bib63" ref-type="bibr">63</xref></sup>) were published between 2002<sup><xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib44" ref-type="bibr">44</xref></sup> and 2024<sup><xref rid="bib22" ref-type="bibr">22</xref></sup> in Denmark<sup><xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib43" ref-type="bibr">43</xref></sup>, Egypt<sup><xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib63" ref-type="bibr">63</xref></sup>, the U.S.A.<sup><xref rid="bib23" ref-type="bibr">23</xref>-<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib37" ref-type="bibr">37</xref>-<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib55" ref-type="bibr">55</xref>,<xref rid="bib57" ref-type="bibr">57</xref>-<xref rid="bib61" ref-type="bibr">61</xref></sup>, Germany<sup><xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib52" ref-type="bibr">52</xref>-<xref rid="bib54" ref-type="bibr">54</xref>,<xref rid="bib62" ref-type="bibr">62</xref></sup>, South Korea<sup><xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref></sup>, Australia<sup><xref rid="bib29" ref-type="bibr">29</xref></sup>, the People&#8217;s Republic of China<sup><xref rid="bib30" ref-type="bibr">30</xref></sup>, The Netherlands<sup><xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib33" ref-type="bibr">33</xref></sup>, Spain<sup><xref rid="bib36" ref-type="bibr">36</xref></sup>, the Czech Republic<sup><xref rid="bib40" ref-type="bibr">40</xref></sup>, Canada<sup><xref rid="bib41" ref-type="bibr">41</xref></sup>, Sweden<sup><xref rid="bib44" ref-type="bibr">44</xref></sup>, Japan<sup><xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib50" ref-type="bibr">50</xref></sup>, Brazil<sup><xref rid="bib48" ref-type="bibr">48</xref>,<xref rid="bib51" ref-type="bibr">51</xref></sup>, and Belgium<sup><xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib56" ref-type="bibr">56</xref></sup>. Among these, 4 studies<sup><xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib58" ref-type="bibr">58</xref>,<xref rid="bib59" ref-type="bibr">59</xref></sup> were later follow-ups of previous reports<sup><xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib57" ref-type="bibr">57</xref></sup>. Collectively, 3,823 patients with a mean age of 55.7 years, a female proportion of 58%, and a mean body mass index (BMI) of 26.5 kg/m<sup>2</sup> were analyzed. Follow-up ranged from 12 to 60 months. The surgical techniques performed encompassed transforaminal lumbar interbody fusion (TLIF)<sup><xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib61" ref-type="bibr">61</xref>-<xref rid="bib63" ref-type="bibr">63</xref></sup>, posterolateral fusion (PLF; either uninstrumented<sup><xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib57" ref-type="bibr">57</xref>-<xref rid="bib60" ref-type="bibr">60</xref></sup> or instrumented<sup><xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib30" ref-type="bibr">30</xref>-<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib50" ref-type="bibr">50</xref>,<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib53" ref-type="bibr">53</xref></sup>), anterior lumbar interbody fusion (ALIF)<sup><xref rid="bib23" ref-type="bibr">23</xref>-<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib52" ref-type="bibr">52</xref>-<xref rid="bib55" ref-type="bibr">55</xref></sup>, posterior lumbar interbody fusion (PLIF)<sup><xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib56" ref-type="bibr">56</xref></sup>, and extreme lateral interbody fusion (XLIF)<sup><xref rid="bib48" ref-type="bibr">48</xref>,<xref rid="bib51" ref-type="bibr">51</xref></sup>. Osteobiologics included AICBG<sup><xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib23" ref-type="bibr">23</xref>-<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib30" ref-type="bibr">30</xref>-<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib48" ref-type="bibr">48</xref>-<xref rid="bib50" ref-type="bibr">50</xref>,<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib55" ref-type="bibr">55</xref>-<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib62" ref-type="bibr">62</xref></sup>, autologous local bone (ALB)<sup><xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib45" ref-type="bibr">45</xref>-<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib50" ref-type="bibr">50</xref>,<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib61" ref-type="bibr">61</xref>-<xref rid="bib63" ref-type="bibr">63</xref></sup>, rhBMP-2<sup><xref rid="bib23" ref-type="bibr">23</xref>-<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib37" ref-type="bibr">37</xref>-<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib61" ref-type="bibr">61</xref></sup>, allograft<sup><xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib53" ref-type="bibr">53</xref>-<xref rid="bib55" ref-type="bibr">55</xref>,<xref rid="bib61" ref-type="bibr">61</xref></sup>, rhBMP-7<sup><xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib57" ref-type="bibr">57</xref>-<xref rid="bib60" ref-type="bibr">60</xref></sup>, titanium cages<sup><xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib55" ref-type="bibr">55</xref></sup>, platelet-rich plasma (PRP)<sup><xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib63" ref-type="bibr">63</xref></sup>, anorganic bone matrix/15-amino acid peptide fragment (ABM/P-15)<sup><xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib43" ref-type="bibr">43</xref></sup>, bioglass<sup><xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref></sup>, demineralized bone matrix (DBM)<sup><xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib45" ref-type="bibr">45</xref></sup>, silicate-substituted calcium phosphate (SiCaP)<sup><xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib51" ref-type="bibr">51</xref></sup>, &#946;-tricalcium phosphate (&#946;-TCP)<sup><xref rid="bib30" ref-type="bibr">30</xref></sup>, biphasic calcium phosphate (BCP)<sup><xref rid="bib41" ref-type="bibr">41</xref></sup>, bone marrow-derived stromal cells (BM-MSC)<sup><xref rid="bib36" ref-type="bibr">36</xref></sup>, bone marrow aspirate (BMA)<sup><xref rid="bib26" ref-type="bibr">26</xref></sup>, bone marrow concentrate (BMC)<sup><xref rid="bib40" ref-type="bibr">40</xref></sup>, ceramic bone graft substitute (CBGS)<sup><xref rid="bib48" ref-type="bibr">48</xref></sup>, silica gel matrix (NH-SiO<sub>2</sub>)<sup><xref rid="bib54" ref-type="bibr">54</xref></sup>, polyetheretherketone (PEEK) cages<sup><xref rid="bib61" ref-type="bibr">61</xref></sup>, periosteal cells<sup><xref rid="bib52" ref-type="bibr">52</xref></sup>, platelet-rich fibrin (PRF)<sup><xref rid="bib63" ref-type="bibr">63</xref></sup>, and hydroxyapatite (HA)<sup><xref rid="bib62" ref-type="bibr">62</xref></sup>. General characteristics of the included studies are summarized in Table I and Appendix eTable 2. Overall, 8 studies (18.6%) had a low risk of bias, 13 (30.2%) had &#8220;some concerns,&#8221; and 22 (51.2%) had a high risk of bias (see Appendix eFigure 1).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE I</label><caption><p>General Characteristics and Patient Demographics of Included Studies<xref rid="tblfn1" ref-type="table-fn">*</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Funding</th><th align="center" rowspan="1" colspan="1">Patient Diagnosis</th><th align="center" rowspan="1" colspan="1">Type of Surgery</th><th align="center" rowspan="1" colspan="1">Last Follow-up <italic toggle="yes">(mo)</italic></th><th align="center" rowspan="1" colspan="1">Treatment Groups</th><th align="center" rowspan="1" colspan="1">No. of Patients</th><th align="center" rowspan="1" colspan="1">Age<xref rid="tblfn2" ref-type="table-fn">&#8224;</xref>
<italic toggle="yes">(yr)</italic></th><th align="center" rowspan="1" colspan="1">Sex, M/F</th><th align="center" rowspan="1" colspan="1">BMI<xref rid="tblfn2" ref-type="table-fn">&#8224;</xref>
<italic toggle="yes">(kg/m</italic><sup><italic toggle="yes">2</italic></sup><italic toggle="yes">)</italic></th><th align="center" rowspan="1" colspan="1">Smokers</th><th align="center" rowspan="1" colspan="1">Lost to Follow-up</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Abou-Madawi 2022<sup><xref rid="bib21" ref-type="bibr">21</xref></sup></td><td rowspan="2" colspan="1">Egypt</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">1-level grade I-II spondylolisthesis not responding to conservative treatment &gt;3 months</td><td rowspan="2" colspan="1">TLIF</td><td rowspan="2" align="center" colspan="1">&#8805;24</td><td rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">47.0 &#177; 18.0</td><td rowspan="1" colspan="1">30/24</td><td rowspan="1" colspan="1">24.9 &#177; 5.3</td><td rowspan="1" colspan="1">10</td><td rowspan="2" colspan="1">13 total</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">49.0 &#177; 18.0</td><td rowspan="1" colspan="1">27/27</td><td rowspan="1" colspan="1">23.5 &#177; 4.5</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="2" colspan="1">Andresen 2024<sup><xref rid="bib22" ref-type="bibr">22</xref></sup><xref rid="tblfn5" ref-type="table-fn">#</xref></td><td rowspan="2" colspan="1">Denmark</td><td rowspan="2" colspan="1">Cerapedics</td><td rowspan="2" colspan="1">LSS with 1- or 2-level DLS</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">60</td><td rowspan="1" colspan="1">ABM/P-15 + ALB</td><td align="center" rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">71.4 &#177; 6.3</td><td rowspan="1" colspan="1">8/35</td><td rowspan="1" colspan="1">27.4 &#177; 4.0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">7, 22<xref rid="tblfn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td rowspan="1" colspan="1">Allograft + ALB</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">70.1 &#177; 6.8</td><td rowspan="1" colspan="1">8/32</td><td rowspan="1" colspan="1">26.9 &#177; 3.9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11, 21<xref rid="tblfn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td rowspan="2" colspan="1">Burkus 2002a<sup><xref rid="bib23" ref-type="bibr">23</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1-level lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Standalone ALIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">Allograft + rhBMP-2</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">41.5</td><td rowspan="1" colspan="1">16/8</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Allograft + AICBG</td><td align="center" rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">45.6</td><td rowspan="1" colspan="1">10/12</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="2" colspan="1">Burkus 2002b<sup><xref rid="bib24" ref-type="bibr">24</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">1-level lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Standalone ALIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">143</td><td rowspan="1" colspan="1">43.3</td><td rowspan="1" colspan="1">78/65</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">42.3</td><td rowspan="1" colspan="1">68/68</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">13</td></tr><tr><td rowspan="2" colspan="1">Burkus 2005<sup><xref rid="bib25" ref-type="bibr">25</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1-level lumbar IDD &#177; grade I DLS not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Standalone ALIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">Allograft + rhBMP-2</td><td align="center" rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">40.2</td><td rowspan="1" colspan="1">32/47</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Allograft + AICBG</td><td align="center" rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">43.6</td><td rowspan="1" colspan="1">19/33</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="2" colspan="1">Chatterjee 2020<sup><xref rid="bib26" ref-type="bibr">26</xref></sup></td><td rowspan="2" colspan="1">Germany</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">IDD, post-laminectomy syndrome, spondylolisthesis, LSS, failed discectomy, recurrent LDH between L2-L3 and L5-S1</td><td rowspan="2" colspan="1">ALIF with plated cage or pedicle screw fixation</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">Allograft</td><td align="center" rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">59.0 &#177; 14.6</td><td rowspan="1" colspan="1">4/17</td><td rowspan="1" colspan="1">25.5 &#177; 4.4</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Allograft + BMA</td><td align="center" rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">58.3 &#177; 34.0</td><td rowspan="1" colspan="1">10/11</td><td rowspan="1" colspan="1">27.4 &#177; 5.3</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="2" colspan="1">Cho 2023<sup><xref rid="bib27" ref-type="bibr">27</xref></sup></td><td rowspan="2" colspan="1">South Korea</td><td rowspan="2" colspan="1">CGBio/BioAlpha</td><td rowspan="2" colspan="1">1-level LSS, grade 1 DLS or spondylolysis</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">36</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">63.2 &#177; 8.2</td><td rowspan="1" colspan="1">17/15</td><td rowspan="1" colspan="1">25.2 &#177; 3.3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">60.8 &#177; 9.0</td><td rowspan="1" colspan="1">18/23</td><td rowspan="1" colspan="1">25.9 &#177; 3.3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="2" colspan="1">Coughlan 2018<sup><xref rid="bib29" ref-type="bibr">29</xref></sup></td><td rowspan="2" colspan="1">Australia</td><td rowspan="2" colspan="1">Baxter Healthcare</td><td rowspan="2" colspan="1">1- or 2-level lumbar IDD, spondylolisthesis or LDH not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">PLIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">SiCaP</td><td align="center" rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">50.8 &#177; 11.4</td><td rowspan="1" colspan="1">27/24</td><td rowspan="1" colspan="1">26.9 &#177; 4.3</td><td rowspan="1" colspan="1">42</td><td rowspan="2" colspan="1">4 total</td></tr><tr><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">52.3 &#177; 11.6</td><td rowspan="1" colspan="1">28/24</td><td rowspan="1" colspan="1">28.6 &#177; 5.0</td><td rowspan="1" colspan="1">41</td></tr><tr><td rowspan="2" colspan="1">Dai 2008<sup><xref rid="bib30" ref-type="bibr">30</xref></sup></td><td rowspan="2" colspan="1">People&#8217;s Republic of China</td><td rowspan="2" colspan="1">Shanghai Natural Science Foundation</td><td rowspan="2" colspan="1">1-level LSS</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">36</td><td rowspan="1" colspan="1">&#946;-TCP + ALB</td><td align="center" rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">48-72</td><td rowspan="1" colspan="1">14/18</td><td rowspan="1" colspan="1">23-32</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">51-73</td><td rowspan="1" colspan="1">11/19</td><td rowspan="1" colspan="1">20-31</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Dawson 2009<sup><xref rid="bib31" ref-type="bibr">31</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1- or 2-level lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">55.9</td><td rowspan="1" colspan="1">10/15</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">56.9</td><td rowspan="1" colspan="1">9/12</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Delawi 2010<sup><xref rid="bib32" ref-type="bibr">32</xref></sup></td><td rowspan="2" colspan="1">The Netherlands</td><td rowspan="2" colspan="1">Corporate/industry</td><td rowspan="2" colspan="1">1-level grade I-II isthmic or DLS</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">rhBMP-7 + ALB</td><td align="center" rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">53.0 &#177; 18.0</td><td rowspan="1" colspan="1">10/8</td><td rowspan="1" colspan="1">26.0 &#177; 4.0</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">55.0 &#177; 13.0</td><td rowspan="1" colspan="1">6/10</td><td rowspan="1" colspan="1">27.0 &#177; 3.0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Delawi 2016<sup><xref rid="bib33" ref-type="bibr">33</xref></sup></td><td rowspan="2" colspan="1">The Netherlands</td><td rowspan="2" colspan="1">Stryker</td><td rowspan="2" colspan="1">1-level DLS or isthmic spondylolisthesis with central or foraminal LSS</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">rhBMP-7 + ALB</td><td align="center" rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">54.0 &#177; 14.0</td><td rowspan="1" colspan="1">27/33</td><td rowspan="1" colspan="1">26.6 &#177; 4.0</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">55.0 &#177; 13.0</td><td rowspan="1" colspan="1">25/34</td><td rowspan="1" colspan="1">25.2 &#177; 5.0</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Dimar 2006<sup><xref rid="bib34" ref-type="bibr">34</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">1-level symptomatic lumbar IDD &gt;6 months</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">52.7</td><td rowspan="1" colspan="1">20/25</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">50.9</td><td rowspan="1" colspan="1">22/31</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="2" colspan="1">Dimar 2009<sup><xref rid="bib35" ref-type="bibr">35</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1-level symptomatic lumbar IDD &gt;6 months</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">239</td><td rowspan="1" colspan="1">53.2 (20-81)</td><td rowspan="1" colspan="1">108/131</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">23</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">224</td><td rowspan="1" colspan="1">52.3 (18-86)</td><td rowspan="1" colspan="1">95/129</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">33</td></tr><tr><td rowspan="2" colspan="1">Garc&#237;a de Frutos 2020<sup><xref rid="bib36" ref-type="bibr">36</xref></sup></td><td rowspan="2" colspan="1">Spain</td><td rowspan="2" colspan="1">Government funding</td><td rowspan="2" colspan="1">Grade I-II DLS &#177; lumbar 1- or 2-level(s) IDD</td><td rowspan="2" colspan="1">TLIF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">BM-MSCs + allograft + AICBG</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">61.0 &#177; 14.6</td><td rowspan="1" colspan="1">9/25</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">60.5 &#177; 10.3</td><td rowspan="1" colspan="1">14/21</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="2" colspan="1">Glassman 2005<sup><xref rid="bib37" ref-type="bibr">37</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Cooperate/industry</td><td rowspan="2" colspan="1">1-level lumbar IDD &#177; grade I DLS not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">14/24</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">16/20</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Glassman 2008<sup><xref rid="bib38" ref-type="bibr">38</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Norton Healthcare</td><td rowspan="2" colspan="1">IDD, LSS, DLS, deformity, post-decompression revision between L1-S1</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2 + ALB</td><td align="center" rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">69.2 &#177; 5.5</td><td rowspan="1" colspan="1">15/35</td><td rowspan="1" colspan="1">29.4 &#177; 5.7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">69.9 &#177; 5.8</td><td rowspan="1" colspan="1">17/35</td><td rowspan="1" colspan="1">28.1 &#177; 6.1</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Haid 2004<sup><xref rid="bib39" ref-type="bibr">39</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">1-level lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">Standalone PLIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">46.3 (25.8-66.1)</td><td rowspan="1" colspan="1">17/17</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">46.1 (28.5-70.9)</td><td rowspan="1" colspan="1">15/18</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Hart 2014<sup><xref rid="bib40" ref-type="bibr">40</xref></sup></td><td rowspan="2" colspan="1">The Czech Republic</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">Lumbar IDD</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">Allograft</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">62.7 (47-77)</td><td rowspan="1" colspan="1">10/30</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Allograft + BMC</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">58.5 (42-80)</td><td rowspan="1" colspan="1">12/28</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Hurlbert 2013<sup><xref rid="bib41" ref-type="bibr">41</xref></sup></td><td rowspan="2" colspan="1">Canada</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1- or 2-level lumbar IDD</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">48</td><td rowspan="1" colspan="1">rhBMP-2 + BCP</td><td align="center" rowspan="1" colspan="1">98</td><td rowspan="1" colspan="1">53.0</td><td rowspan="1" colspan="1">35/63</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">AIBCG</td><td align="center" rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">53.0</td><td rowspan="1" colspan="1">48/51</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="2" colspan="1">Hyun 2021<sup><xref rid="bib42" ref-type="bibr">42</xref></sup></td><td rowspan="2" colspan="1">South Korea</td><td rowspan="2" colspan="1">Government funding</td><td rowspan="2" colspan="1">1- or 2-level IDD between L3-S1</td><td rowspan="2" colspan="1">TLIF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">DBM + rhBMP-2 + ALB</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">64.0 &#177; 10.3</td><td rowspan="1" colspan="1">23/17</td><td rowspan="1" colspan="1">24.3 &#177; 2.7</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">DBM + ALB</td><td align="center" rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">62.7 &#177; 9.3</td><td rowspan="1" colspan="1">19/17</td><td rowspan="1" colspan="1">26.2 &#177; 4.2</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Jacobsen 2020<sup><xref rid="bib43" ref-type="bibr">43</xref></sup></td><td rowspan="2" colspan="1">Denmark</td><td rowspan="2" colspan="1">Orthotech</td><td rowspan="2" colspan="1">LSS with 1- or 2-level DLS</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">ABM/P-15 + ALB</td><td align="center" rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">71.4 &#177; 6.3</td><td rowspan="1" colspan="1">14/35</td><td rowspan="1" colspan="1">27.4 &#177; 4.0</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Allograft + ALB</td><td align="center" rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">70.1 &#177; 6.8</td><td rowspan="1" colspan="1">10/39</td><td rowspan="1" colspan="1">26.9 &#177; 3.9</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Johnsson 2002<sup><xref rid="bib44" ref-type="bibr">44</xref></sup></td><td rowspan="2" colspan="1">Sweden</td><td rowspan="2" colspan="1">Cooperate/industry</td><td rowspan="2" colspan="1">Grade I-II isthmic spondylolisthesis</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">rhBMP-7</td><td align="center" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">42.9 &#177; 10.8</td><td rowspan="1" colspan="1">3/7</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">40.4 &#177; 9.6</td><td rowspan="1" colspan="1">5/5</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Kang 2012<sup><xref rid="bib45" ref-type="bibr">45</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Osteotech</td><td rowspan="2" colspan="1">1-level DLS with LSS</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">DBM + ALB</td><td align="center" rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">64.3</td><td rowspan="1" colspan="1">10/18</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">65.3</td><td rowspan="1" colspan="1">5/8</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Kubota 2019<sup><xref rid="bib28" ref-type="bibr">28</xref></sup></td><td rowspan="2" colspan="1">Japan</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">LSS with unstable DLS</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">PRP + ALB</td><td align="center" rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">65.1 &#177; 2.1</td><td rowspan="1" colspan="1">15/10</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">65.3 &#177; 2.0</td><td rowspan="1" colspan="1">14/11</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="2" colspan="1">Lee 2016<sup><xref rid="bib46" ref-type="bibr">46</xref></sup></td><td rowspan="2" colspan="1">South Korea</td><td rowspan="2" colspan="1">CGBio/BioAlpha</td><td rowspan="2" colspan="1">Severe disc extrusion, LSS, or grade I-II DLS</td><td rowspan="2" colspan="1">PLIF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">Bioglass + ALB</td><td align="center" rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">61.5 &#177; 9.4</td><td rowspan="1" colspan="1">12/27</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Titanium cage + ALB</td><td align="center" rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">61.1 &#177; 8.3</td><td rowspan="1" colspan="1">14/21</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Lee 2020<sup><xref rid="bib47" ref-type="bibr">47</xref></sup>,<xref rid="tblfn4" ref-type="table-fn">&#167;</xref></td><td rowspan="2" colspan="1">South Korea</td><td rowspan="2" colspan="1">CGBio/BioAlpha</td><td rowspan="2" colspan="1">Severe disc extrusion, LSS, or grade I-II DLS</td><td rowspan="2" colspan="1">PLIF</td><td rowspan="2" align="center" colspan="1">48</td><td rowspan="1" colspan="1">Bioglass + ALB</td><td align="center" rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">61.5 &#177; 8.9</td><td rowspan="1" colspan="1">8/24</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">Titanium cage + ALB</td><td align="center" rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">61.1 &#177; 8.3</td><td rowspan="1" colspan="1">12/18</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="2" colspan="1">Menezes 2022<sup><xref rid="bib48" ref-type="bibr">48</xref></sup></td><td rowspan="2" colspan="1">Brazil</td><td rowspan="2" colspan="1">Nuvasive</td><td rowspan="2" colspan="1">1-level lumbar IDD</td><td rowspan="2" colspan="1">XLIF + pedicle screw fixation</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">CBGS</td><td align="center" rowspan="1" colspan="1">30</td><td rowspan="2" colspan="1">57.0 &#177; 3.8 overall</td><td rowspan="2" colspan="1">22/23 overall</td><td rowspan="2" colspan="1">26.8 &#177; 4.1 overall</td><td rowspan="2" colspan="1">3 total</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="2" colspan="1">Michielsen 2013<sup><xref rid="bib49" ref-type="bibr">49</xref></sup></td><td rowspan="2" colspan="1">Belgium</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">1-level isthmic or DLS, lumbar IDD not responding to conservative treatment &gt;6 months, LDH with severe IDD not responding to ESI</td><td rowspan="2" colspan="1">PLIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">43.2 &#177; 8.8</td><td rowspan="1" colspan="1">6/13</td><td rowspan="1" colspan="1">27.0 &#177; 3.2</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">42.2 &#177; 9.7</td><td rowspan="1" colspan="1">10/9</td><td rowspan="1" colspan="1">24.6 &#177; 3.4</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" colspan="1">Mohi El din 2021<sup><xref rid="bib63" ref-type="bibr">63</xref></sup></td><td rowspan="3" colspan="1">Egypt</td><td rowspan="3" colspan="1">None</td><td rowspan="3" colspan="1">1-level isthmic or DLS or IDD not responding to conservative treatment &gt;6 months</td><td rowspan="3" colspan="1">TLIF</td><td rowspan="3" align="center" colspan="1">12</td><td rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">45.1 &#177; 9.9</td><td rowspan="1" colspan="1">17/23</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">PRF</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">47.4 &#177; 6.2</td><td rowspan="1" colspan="1">10/10</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">PRP</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">44.1 &#177; 4.5</td><td rowspan="1" colspan="1">9/11</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="2" colspan="1">Ohtori 2011<sup><xref rid="bib50" ref-type="bibr">50</xref></sup></td><td rowspan="2" colspan="1">Japan</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">L4-L5 DLS with LSS and chronic LBP &gt;12 months</td><td rowspan="2" colspan="1">Instrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">66.0 &#177; 5.5</td><td rowspan="1" colspan="1">22/20</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">ALB + AICBG</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">67.0 &#177; 6.0</td><td rowspan="1" colspan="1">18/22</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" colspan="1">Pimenta 2013<sup><xref rid="bib51" ref-type="bibr">51</xref></sup></td><td rowspan="2" colspan="1">Brazil</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">L4-L5 IDD not responding to conservative treatment</td><td rowspan="2" colspan="1">Standalone XLIF</td><td rowspan="2" align="center" colspan="1">36</td><td rowspan="1" colspan="1">SiCaP</td><td align="center" rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">49.1 &#177; 10.7</td><td rowspan="1" colspan="1">4/11</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">rhBMP-2</td><td align="center" rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">45.7 &#177; 11.4</td><td rowspan="1" colspan="1">7/8</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Putzier 2008<sup><xref rid="bib52" ref-type="bibr">52</xref></sup></td><td rowspan="2" colspan="1">Germany</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">1-level lumbar IDD or grade I-II spondylolisthesis</td><td rowspan="2" colspan="1">ALIF + instrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">49.3 (34-60)</td><td rowspan="2" align="center" colspan="1">12/12 overall</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Periosteal cells + ALB</td><td align="center" rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">46.4 (34-58)</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="2" colspan="1">Putzier 2009<sup><xref rid="bib53" ref-type="bibr">53</xref></sup></td><td rowspan="2" colspan="1">Germany</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">L4-L5 or L5-S1 lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">ALIF + instrumented PLF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">Allograft + ALB</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">45.5 (34-62)</td><td rowspan="1" colspan="1">10/10</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">AICBG + ALB</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">45.4 (26-62)</td><td rowspan="1" colspan="1">11/9</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="2" colspan="1">Rickert 2019<sup><xref rid="bib54" ref-type="bibr">54</xref></sup></td><td rowspan="2" colspan="1">Germany</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">L4-L5 or L5-S1 IDD</td><td rowspan="2" colspan="1">ALIF with plated cage or ALIF + pedicle screw fixation</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">NH-SiO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">60.6 &#177; 12.5</td><td rowspan="1" colspan="1">6/14</td><td rowspan="1" colspan="1">26.4 &#177; 4.6</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Allograft</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">66.1 &#177; 9.6</td><td rowspan="1" colspan="1">4/16</td><td rowspan="1" colspan="1">26.5 &#177; 4.9</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Sasso 2004<sup><xref rid="bib55" ref-type="bibr">55</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Cooperate/industry</td><td rowspan="2" colspan="1">1-level symptomatic lumbar IDD &gt;6 months</td><td rowspan="2" colspan="1">Standalone ALIF</td><td rowspan="2" align="center" colspan="1">48</td><td rowspan="1" colspan="1">Titanium cage + AICBG</td><td align="center" rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">41.0 (18-64)</td><td rowspan="1" colspan="1">30/47</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">Allograft + AICBG</td><td align="center" rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">41.2 (27-59)</td><td rowspan="1" colspan="1">33/29</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="2" colspan="1">Sys 2011<sup><xref rid="bib56" ref-type="bibr">56</xref></sup></td><td rowspan="2" colspan="1">Belgium</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">1-level isthmic or DLS, lumbar IDD not responding to conservative treatment &gt;6 months, LDH with severe IDD not responding to ESI</td><td rowspan="2" colspan="1">PLIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">PRP + AICBG</td><td align="center" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">12/7</td><td rowspan="1" colspan="1">27.2 &#177; 5.0</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">12/7</td><td rowspan="1" colspan="1">25.4 &#177; 3.6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="2" colspan="1">Vaccaro 2004<sup><xref rid="bib57" ref-type="bibr">57</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Cooperate/industry</td><td rowspan="2" colspan="1">Grade I-II DLS with LSS not responding to conservative treatment</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">rhBMP-7</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">63.0 &#177; 11.0</td><td rowspan="1" colspan="1">11/13</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">66.0 &#177; 7.0</td><td rowspan="1" colspan="1">5/7</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="2" colspan="1">Vaccaro 2005<sup><xref rid="bib58" ref-type="bibr">58</xref></sup><xref rid="tblfn4" ref-type="table-fn">&#167;</xref></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">Cooperate/industry</td><td rowspan="2" colspan="1">Grade I-II L3-L4 DLS + LSS</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">36</td><td rowspan="1" colspan="1">rhBMP-7</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">63.0 &#177; 11.0</td><td rowspan="1" colspan="1">11/13</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">66.0 &#177; 7.0</td><td rowspan="1" colspan="1">5/7</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="2" colspan="1">Vaccaro 2008a<sup><xref rid="bib60" ref-type="bibr">60</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">Grade I-II DLS with LSS not responding to conservative treatment</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">&#8805;36</td><td rowspan="1" colspan="1">rhBMP-7</td><td align="center" rowspan="1" colspan="1">207</td><td rowspan="1" colspan="1">68.0 &#177; 9.8</td><td rowspan="1" colspan="1">71/136</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">63</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">86</td><td rowspan="1" colspan="1">71.0 &#177; 8.3</td><td rowspan="1" colspan="1">26/60</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">28</td></tr><tr><td rowspan="2" colspan="1">Vaccaro 2008b<sup><xref rid="bib59" ref-type="bibr">59</xref></sup><xref rid="tblfn4" ref-type="table-fn">&#167;</xref></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">NS</td><td rowspan="2" colspan="1">Grade I-II DLS with LSS not responding to conservative treatment</td><td rowspan="2" colspan="1">Uninstrumented PLF</td><td rowspan="2" align="center" colspan="1">48</td><td rowspan="1" colspan="1">rhBMP-7</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">63.0 (43-80)</td><td rowspan="1" colspan="1">11/13</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">67.0 (51-79)</td><td rowspan="1" colspan="1">5/7</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">Excluded</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="2" colspan="1">Villavicencio 2022<sup><xref rid="bib61" ref-type="bibr">61</xref></sup></td><td rowspan="2" colspan="1">U.S.A.</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">Chronic LBP due to IDD with LSS, spondylolisthesis, or recurrent LDH not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">TLIF</td><td rowspan="2" align="center" colspan="1">24</td><td rowspan="1" colspan="1">Allograft + rhBMP-2 + ALB</td><td align="center" rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">59.9 &#177; 10.4</td><td rowspan="1" colspan="1">31/29</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">PEEK + rhBMP-2 + ALB</td><td align="center" rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">62.2 &#177; 10.7</td><td rowspan="1" colspan="1">32/29</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">vonderHoeh 2017<sup><xref rid="bib62" ref-type="bibr">62</xref></sup></td><td rowspan="2" colspan="1">Germany</td><td rowspan="2" colspan="1">Medtronic</td><td rowspan="2" colspan="1">1- or 2-level lumbar IDD not responding to conservative treatment &gt;6 months</td><td rowspan="2" colspan="1">TLIF</td><td rowspan="2" align="center" colspan="1">12</td><td rowspan="1" colspan="1">ALB + HA</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">64.3 &#177; 12.6</td><td rowspan="1" colspan="1">7/17</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">AICBG</td><td align="center" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">65.6 &#177; 14.4</td><td rowspan="1" colspan="1">5/19</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="tblfn1"><label>*</label><p>ABM/P-15 = anorganic bone matrix/15-amino acid peptide fragment, ALB = autologous local bone, AICBG = autologous iliac crest bone graft, ALIF = anterior lumbar interbody fusion, BCP = biphasic calcium phosphate, &#946;-TCP = &#946;-tricalcium phosphate, BM-MSCs = bone marrow-derived mesenchymal stromal cells, BMA = bone marrow aspirate, BMC = bone marrow concentrate, BMI = body mass index, CBGS = ceramic bone graft substitute, DBM = demineralized bone matrix, DLS = degenerative spondylolisthesis, ESI = epidural steroid injection, HA = hydroxyapatite, IDD = intervertebral disc degeneration, LBP = low back pain, LDH = lumbar disc herniation, LSS = lumbar spinal stenosis, NH-SiO<sub>2</sub> = silica gel matrix, NS = not specified, PEEK = polyetheretherketone, PLF = posterolateral fusion, PLIF = posterior lumbar interbody fusion, PRF = platelet-rich fibrin, PRP = platelet-rich plasma, rhBMP = recombinant human bone morphogenetic protein, SiCaP = silicate-substituted calcium phosphate, TLIF = transforaminal lumbar interbody fusion, XLIF = extreme lateral interbody fusion.</p></fn><fn fn-type="other" id="tblfn2"><label>&#8224;</label><p>Values are given as the mean, mean &#177; standard deviation, mean (range), or range.</p></fn><fn fn-type="other" id="tblfn3"><label>&#8225;</label><p>At the last follow-up, clinical outcomes were available for 7 and 11 patients and fusion outcomes were available for 22 and 21 patients in the ABM/P-15 + ALB and Allograft + ALB groups, respectively.</p></fn><fn fn-type="other" id="tblfn4"><label>&#167;</label><p>Later follow-up report of the preceding study.</p></fn><fn fn-type="other" id="tblfn5"><label>#</label><p>Later follow-up report of the study by Jacobsen et al.<sup><xref rid="bib43" ref-type="bibr">43</xref></sup>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Fusion Rate</title><p>The NMA for fusion rate included 30 RCTs with a total of 2,671 patients and 18 different combinations of osteobiologics (Fig. <xref rid="fig2" ref-type="fig">2</xref>-A; see also Appendix eTable 3). Compared with AICBG, rhBMP-2 showed a significantly higher fusion rate (OR: 3.71; 95% CI: 2.59 to 5.32; p &lt; 0.0001), while all other treatments showed no significant differences (Fig. <xref rid="fig3" ref-type="fig">3</xref>-A), with low inconsistency and heterogeneity (&#964;<sup>2</sup>: 0%; I<sup>2</sup>: 0% [95% CI: 0.0% to 53.6%]; p = 0.73). No significant publication bias was detected (p = 0.21; see Appendix eFigure 2). The importance of individual studies within the network is depicted in Appendix eFigure 3.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>Fig. 2</label><caption><p>Network meta-analyses of eligible comparisons for fusion (<bold>Fig. 2-A</bold>) and complication rates (<bold>Fig. 2-B</bold>). Line width is proportional to the number of RCTs comparing each individual treatment vs. AICBG. Circle size is proportional to the number of patients receiving the treatment (which is indicated below the circle). ALB = autologous local bone, AICBG = autologous iliac crest bone graft, ABM/P-15 = anorganic bone matrix/15-amino acid peptide fragment, BM-MSCs = bone marrow-derived mesenchymal stromal cells, BMC = bone marrow concentrate, CBGS = ceramic bone graft substitute, DBM = demineralized bone matrix, HA = hydroxyapatite, NHSiO2 = silica gel matrix, PRF = platelet-rich fibrin, PRP = platelet-rich plasma, rhBMP = recombinant human bone morphogenetic protein, SiCaP = silicate-substituted calcium phosphate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jbjsam-107-2110-g002.jpg"/></fig><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>Fig. 3</label><caption><p>Forest plots of network meta-analyses of fusion (<bold>Fig. 3-A</bold>) and complication rates (<bold>Fig. 3-B</bold>) of other osteobiologics compared with AICBG. Each square size is inversely proportional to the precision of the effect estimate (i.e., CI width). Osteobiologics are reported from highest to lowest SUCRA score. ALB = autologous local bone, AICBG = autologous iliac crest bone graft, ABM/P-15 = anorganic bone matrix/15-amino acid peptide fragment, bTCP = &#946;-tricalcium phosphate, BM-MSCs = bone marrow-derived mesenchymal stromal cells, BMC = bone marrow concentrate, CBGS = ceramic bone graft substitute, CI = confidence interval, DBM = demineralized bone matrix, HA = hydroxyapatite, NHSiO<sub>2</sub> = silica gel matrix, OR = odds ratio, PRF = platelet-rich fibrin, PRP = platelet-rich plasma, rhBMP = recombinant human bone morphogenetic protein, SiCaP = silicate-substituted calcium phosphate, SUCRA = surface under the cumulative ranking curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jbjsam-107-2110-g003.jpg"/></fig><p>When subgrouping studies receiving industry funding (10 studies, 1,281 patients) and those funded by nonprivate, governmental, or institutional sources (6 studies, 463 patients), rhBMP-2 demonstrated greater effectiveness than AICBG in both (OR: 3.80; 95% CI: 2.56 to 5.64; p &lt; 0.0001 for industry-funded studies and OR: 3.32; 95% CI: 1.41 to 7.85; p = 0.01 for nonindustry-funded studies; see Appendix eFigure 4-A), whereas rhBMP-7 yielded significantly lower fusion rates than AICBG only in the former (OR: 0.41; 95% CI: 0.19 to 0.87; p = 0.02). The certainty of the evidence was moderate for rhBMP-2 and low to very low for the other osteobiologics (see Appendix eTable 4).</p></sec><sec><title>Complication Rate</title><p>The NMA for complication rates included 29 RCTs with a total of 2,805 patients and 15 different combinations of osteobiologics (Fig. <xref rid="fig2" ref-type="fig">2</xref>-B; see also Appendix eTable 5). The use of rhBMP-2 (OR: 0.30; 95% CI: 0.13 to 0.68; p &lt; 0.0001) showed significantly lower complication rates, while all other treatments were not significantly different from AICBG (Fig. <xref rid="fig3" ref-type="fig">3</xref>-B). A high degree of heterogeneity (&#964;<sup>2</sup>: 4.41%; I<sup>2</sup>: 74.1% [95% CI: 35.7% to 89.6%]; p = 0.004) and no publication bias were detected (p = 0.15; see Appendix eFigure 5). The importance of individual studies within the network is depicted in Appendix eFigure 6. The subgroup analysis of industry-funded (12 studies, 1,634 patients) and nonindustry-funded studies (5 studies, 485 patients) revealed that complications rates were significantly lower for rhBMP-2 compared with AICBG in both (OR: 0.28; 95% CI: 0.09 to 0.90; p = 0.03 for industry-funded, and OR: 0.41; 95% CI: 0.19 to 0.90; p = 0.03 for nonindustry-funded studies) (see Appendix eFigure 4-B). The certainty of the evidence was moderate for rhBMP-2 and low to very low for the other osteobiologics (see Appendix eTable 6).</p><p>Head-to-head comparisons for the primary outcomes are shown in Appendix eFigure 7. The SUCRA scores of each osteobiologic with respect to fusion and complications have been interpolated in a cluster ranking plot in Figure <xref rid="fig4" ref-type="fig">4</xref>. The best-performing osteobiologics (&gt;50% safety and &gt;50% efficacy) were ABM/P-15, allograft + BMC, NH-SiO<sub>2</sub>, and rhBMP-2. Conversely, rhBMP-7, HA + ALB, ALB + AICBG, CBGS, AICBG, and ALB displayed overall lower performance (&lt;50% safety and &lt;50% efficacy).</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>Fig. 4</label><caption><p>Cluster ranking plot of osteobiologic efficacy and safety of the included osteobiologics, based on the SUCRA values for fusion and complications. Values closer to 100% indicate an increased spinal fusion rate or a reduced complication rate, respectively. Dot colors are based on the quadrants: green, &gt;50% SUCRA for safety and efficacy; blue, &gt;50% for safety but &#8804;50% for efficacy; yellow, &#8804;50% for safety but &gt;50% for efficacy; and orange, &#8804;50% for both efficacy and safety. ALB = autologous local bone, AICBG = autologous iliac crest bone graft, ABM/P15 = anorganic bone matrix/15-amino acid peptide fragment, BMC = bone marrow concentrate, CBGS = ceramic bone graft substitute, HA = hydroxyapatite, NHSiO<sub>2</sub> = silica gel matrix, PRP = platelet-rich plasma, rhBMP = recombinant human bone morphogenetic protein, SiCaP = silicate-substituted calcium phosphate, SUCRA = surface under the cumulative ranking curve.,</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jbjsam-107-2110-g004.jpg"/></fig></sec><sec><title>Secondary Outcomes</title><p>The NMA for LBP severity included 13 studies with a total of 900 patients and 12 different combinations of osteobiologics (see Appendix eFigure 8-A). No significant differences between the analyzed treatments and AICBG were found, although the NMA showed a high degree of heterogeneity (&#964;<sup>2</sup>: 7.778; I<sup>2</sup>: 96.9% [95% CI: 93.6% to 98.5%]; p &lt; 0.0001). Similarly, no significant differences were found for the ODI (19 studies, 1,788 patients, 16 different combinations of osteobiologics; see Appendix eFigure 8-B), with a high degree of heterogeneity (&#964;<sup>2</sup>: 4.408; I<sup>2</sup>: 74.1% [95% CI: 35.7% to 89.6%]; p = 0.004). The NMA for operative time (11 studies, 1,143 patients, 7 different combinations of osteobiologics; see Appendix eFigure 8-C) demonstrated that ALB (MD: &#8722;12.0 minutes; 95% CI: &#8722;21.5 to &#8722;2.5 minutes; p = 0.01), SiCaP (MD: &#8722;18.4 minutes; 95% CI: &#8722;28.6 to &#8722;8.3 minutes; p = 0.0004), and rhBMP-2 (MD: &#8722;21.8 minutes; 95% CI: &#8722;28.0 to &#8722;15.7 minutes; p &lt; 0.0001) demonstrated significantly reduced operative times compared with AICBG. No significant heterogeneity was found (&#964;<sup>2</sup>: 0; I<sup>2</sup>: 0% [95% CI: 0% to 74.6%]; p = 0.8371). Regarding blood loss (8 studies, 891 patients, 5 different combinations of osteobiologics; see Appendix eFigure 8-D), rhBMP-2 was significantly more effective compared with AICBG (MD: &#8722;72.6 mL; 95% CI: &#8722;118.9 to &#8722;26.4 mL; p = 0.002), with no significant heterogeneity (&#964;<sup>2</sup>: 960.3; I<sup>2</sup>: 44.5% [95% CI: 0% to 79.7%]; p = 0.13). The analysis of LOS (7 studies, 891 patients, 5 different combinations of osteobiologics; see Appendix eFigure 8-E) showed no significant differences, with low heterogeneity (&#964;<sup>2</sup>: 0; I<sup>2</sup>: 0% [95% CI: 0% to 89.6%]; p = 0.64). No significant publication bias was detected for any of the secondary outcomes (see Appendix eFigures 9-A through 9-E).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study represents the most comprehensive assessment of osteobiologics in LSF to date, revealing critical insights into their efficacy and safety. Among the products analyzed, rhBMP-2 consistently demonstrated the highest fusion rates, significantly outperforming the traditional gold standard, AICBG. These results align with trends in spinal surgery favoring off-the-shelf alternatives due to their availability, reduced operative times, and lower donor-site morbidity<sup><xref rid="bib64" ref-type="bibr">64</xref></sup>. However, the lack of consistency in defining &#8220;successful&#8221; spinal fusion across studies represents a notable limitation, emphasizing the need for a standardized consensus within the spine community to accurately classify and report fusion success<sup><xref rid="bib8" ref-type="bibr">8</xref></sup>. Additionally, while the enhanced fusion rates observed with certain osteobiologics are promising, their long-term impact on clinical outcomes remains underexplored.</p><p>In terms of safety, rhBMP-2 demonstrated significant advantages over AICBG, particularly by abating the risk of donor-site complications. While this product significantly reduced the overall complication rate compared with AICBG, it did not lead to broader improvements in the safety profile of LSF, raising questions about the extent of its clinical benefit beyond fewer complications. It is important to note that our NMA examined overall complication rates, including those considered relevant in the recent AO Spine Guideline for the Use of Osteobiologics (AOGO) Guideline<sup><xref rid="bib65" ref-type="bibr">65</xref></sup>. Not all complications carry the same weight, and a more in-depth analysis of the specific adverse events may be required to fully appraise product safety. Notably, the safety profile of rhBMP-2 has been complicated by controversy in the past, particularly regarding overstating safety outcomes in studies with potential conflicts of interest<sup><xref rid="bib66" ref-type="bibr">66</xref></sup>. Despite the limited number of studies, our analysis revealed significant safety benefits independent of the type of funding source. However, the amount of rhBMP-2 used varied up to 10-fold among studies, which might also have affected the results. Additionally, several osteobiologics have been systematically utilized off-label. For example, rhBMP-2 and ABM/P15 were originally approved for ALIF<sup><xref rid="bib67" ref-type="bibr">67</xref></sup> and anterior cervical interbody fusion only<sup><xref rid="bib68" ref-type="bibr">68</xref></sup>, respectively. This raises further concerns regarding safety issues and possible competing interests related to the use of certain products.</p><p>Despite enhanced fusion rates, the use of osteobiologics did not translate into significant improvements in PROMs for pain or disability. This lack of effect is not surprising, as the recovery trajectory in patients who have undergone LSF is influenced by multiple factors beyond osteobiologics, such as pre-existing conditions, comorbidities, and variations in surgical techniques<sup><xref rid="bib69" ref-type="bibr">69</xref></sup>. Additionally, data on perioperative outcomes, such as blood loss, LOS, and operative time, were sparse. The available data suggest that rhBMP-2 offered benefits in reducing both operative time and blood loss, potentially improving overall surgical outcomes. Similarly, SiCaP, likely due to its off-the-shelf nature, and ALB, which does not require additional time for harvesting, showed shorter operative times. These findings highlight the need for studies with an improved design integrating perioperative outcomes with long-term clinical results to ultimately better inform surgical decision-making and optimize patient care.</p><p>Our study design allowed us to include more RCTs than previous meta-analyses, such as those by Zhang et al. (analyzing 19 RCTs)<sup><xref rid="bib70" ref-type="bibr">70</xref></sup> and Feng et al. (analyzing 27 RCTs)<sup><xref rid="bib71" ref-type="bibr">71</xref></sup>, reflecting the thoroughness of our search strategy. However, our finding that rhBMP-2 improved fusion rates while reducing complication rates contrasts with the latter study<sup><xref rid="bib71" ref-type="bibr">71</xref></sup>. Whereas those authors similarly reported increased fusion rates, they found that rhBMP-2 use was associated with a higher incidence of complications<sup><xref rid="bib71" ref-type="bibr">71</xref></sup>. This discrepancy may be due to their inclusion of a broader range of adverse events, including those not specific to LSF. Additionally, their NMA ranked AICBG higher in terms of safety compared with ours, possibly due to differences in defining complications, such as whether donor-site pain was considered. Moreover, our analysis included a larger number of studies, which could have contributed to the differing results. Notably, products such as SiCaP and NH-SiO<sub>2</sub> ranked relatively high in both safety and efficacy in our analysis, although significance was not reached. Some of our highly ranked products, such as ABM/P15 and allograft + BMC, were not included in the analysis by Feng et al.<sup><xref rid="bib71" ref-type="bibr">71</xref></sup>.</p><p>The potential advantages of off-the-shelf and non-biologically processed osteobiologics, such as SiCaP, NH-SiO<sub>2</sub>, rhBMP-2, and ABM/P15, while requiring further exploration, are promising. Indeed, these products allow for easy scalability and for quality control in specialized environments, and they are not donor-reliant, enabling large-scale production and consistent supply. Over time, this could help reduce costs and expand access to these osteobiologics, making them appealing options for LSF. Although cell-based or cell-derived products, such as allografts, ALB, PRP, and BMC, have demonstrated beneficial outcomes, their effectiveness can be highly dependent on donor quality<sup><xref rid="bib72" ref-type="bibr">72</xref>-<xref rid="bib74" ref-type="bibr">74</xref></sup>. A particular consideration for such autologous products is that patients undergoing LSF often are elderly or affected by underlying health conditions, which may temper product potency. Alternatively, the addition of cells might be advantageous for recipients whose cellular function is compromised due to age or disease, by potentially enhancing the osteogenesis necessary for successful fusion<sup><xref rid="bib75" ref-type="bibr">75</xref></sup>. However, this area requires further investigation to fully understand its implications.</p><p>This NMA has several limitations. Numerous included studies were funded by corporate sponsors. The influence of such funding on the validity, interpretation, and reporting of data remains uncertain, and the results should therefore be interpreted with caution, especially considering the contentious history of rhBMP-2 in cervical and lumbar fusion surgery<sup><xref rid="bib66" ref-type="bibr">66</xref></sup>. Nonetheless, our analysis showed significant and relevant improvements with rhBMP-2 regardless of the funding source, supporting its use for LSF. The heterogeneity in patient populations, surgical techniques, instrumentation, and outcome definitions challenged the assumption of transitivity, which is crucial for valid indirect comparisons in NMAs. Variability in reported data, such as follow-up durations and fusion success criteria, complicated comparisons and might have introduced bias. The general high-to-moderate risk of bias in the included RCTs adds uncertainty to the findings. Additionally, the underrepresentation of several osteobiologics in the current published literature may have skewed the results toward rhBMP-2, AICBG, and other well-represented grafts, thereby potentially limiting the generalizability of our findings in a wider real-world scenario. Furthermore, there is a critical need for more high-quality, publicly funded trials, as current funding sources appear to influence outcomes such as complication rates. Considering the substantial socioeconomic burden of LBP, it is imperative that governments and insurance companies allocate more resources to investigate the cost-effectiveness of these osteobiologics. Additionally, spine professionals must advocate for greater investment in such high-quality studies to ensure evidence-based decision-making.</p><sec sec-type="conclusions"><title>Conclusions</title><p>In this systematic review and NMA, we found that rhBMP-2 use was associated with significantly enhanced fusion, lower complication rates, decreased blood loss, and shorter operative time compared with AICBG. However, the lower complication rates in funded studies suggest potential bias, highlighting the need for cautious interpretation and further investigation. Additionally, the underrepresentation of several osteobiologics in the published literature substantially limits the generalizability of these findings.</p></sec></sec><sec><title>Appendix</title><p>Supporting material provided by the authors is posted with the online version of this article as a data supplement at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://jbjs.org" ext-link-type="uri">jbjs.org</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JBJS/I741" ext-link-type="uri">http://links.lww.com/JBJS/I741</ext-link>).</p></sec></body><back><fn-group><fn fn-type="other" id="fn1"><p><bold>A commentary by Thomas W. Bauer, MD, PhD,</bold> is linked to the online version of this article.</p></fn><fn fn-type="COI-statement" id="fn2"><p><bold>Disclosure:</bold> The project 23-198 was supported by a literature grant from the ON Foundation, Switzerland. The <bold>Disclosure of Potential Conflicts of Interest</bold> forms are provided with the online version of the article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JBJS/I740" ext-link-type="uri">http://links.lww.com/JBJS/I740</ext-link>).</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Muthu</surname><given-names>S</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hamouda</surname><given-names>W</given-names></name><name name-style="western"><surname>Ambrosio</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>JPY</given-names></name><name name-style="western"><surname>Le</surname><given-names>HV</given-names></name><name name-style="western"><surname>Vadal&#224;</surname><given-names>G</given-names></name><name name-style="western"><surname>Buser</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Diwan</surname><given-names>AD</given-names></name></person-group>; <collab>AO Spine Knowledge Forum Degenerative</collab>. <article-title>Clinical effectiveness of reduction and fusion versus in situ fusion in the management of degenerative lumbar spondylolisthesis: a systematic review and meta-analysis</article-title>. <source>Eur Spine J.</source><year>2024</year> May;<volume>33</volume>(<issue>5</issue>):<fpage>1748</fpage>-<lpage>61</lpage>.<pub-id pub-id-type="pmid">38043128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-023-08041-4</pub-id></mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>DS</given-names></name><name name-style="western"><surname>Baker</surname><given-names>KC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>WK</given-names></name></person-group>. <article-title>Lumbar pseudarthrosis: a review of current diagnosis and treatment</article-title>. <source>Neurosurg Focus.</source><year>2015</year> Oct;<volume>39</volume>(<issue>4</issue>):<fpage>E10</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2015.7.FOCUS15292</pub-id><pub-id pub-id-type="pmid">26424334</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boonsirikamchai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wilartratsami</surname><given-names>S</given-names></name><name name-style="western"><surname>Ruangchainikom</surname><given-names>M</given-names></name><name name-style="western"><surname>Korwutthikulrangsri</surname><given-names>E</given-names></name><name name-style="western"><surname>Tongsai</surname><given-names>S</given-names></name><name name-style="western"><surname>Luksanapruksa</surname><given-names>P</given-names></name></person-group>. <article-title>Pseudarthrosis risk factors in lumbar fusion: a systematic review and meta-analysis</article-title>. <source>BMC Musculoskelet Disord.</source><year>2024</year> Jun 3;<volume>25</volume>(<issue>1</issue>):<fpage>433</fpage>.<pub-id pub-id-type="pmid">38831392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12891-024-07531-w</pub-id><pub-id pub-id-type="pmcid">PMC11149252</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadala&#8217;</surname><given-names>G</given-names></name><name name-style="western"><surname>Russo</surname><given-names>F</given-names></name><name name-style="western"><surname>Ambrosio</surname><given-names>L</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>A</given-names></name><name name-style="western"><surname>Papalia</surname><given-names>R</given-names></name><name name-style="western"><surname>Denaro</surname><given-names>V</given-names></name></person-group>. <article-title>Biotechnologies and Biomaterials in Spine Surgery</article-title>. <source>J Biol Regul Homeost Agents.</source><year>2015</year> Oct-Dec;<volume>29</volume>(<issue>4</issue>)<comment>(Suppl)</comment>:<fpage>137</fpage>-<lpage>47</lpage>.<pub-id pub-id-type="pmid">26652500</pub-id></mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Ha</surname><given-names>KY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Rhyu</surname><given-names>KW</given-names></name><name name-style="western"><surname>Park</surname><given-names>JB</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Park</surname><given-names>HY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SI</given-names></name></person-group>. <article-title>Lumbar Interbody Fusion and Osteobiologics for Lumbar Fusion</article-title>. <source>Asian Spine J.</source><year>2022</year> Dec;<volume>16</volume>(<issue>6</issue>):<fpage>1022</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">36573302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31616/asj.2022.0435</pub-id><pub-id pub-id-type="pmcid">PMC9827209</pub-id></mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haws</surname><given-names>BE</given-names></name><name name-style="western"><surname>Khechen</surname><given-names>B</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DV</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JS</given-names></name><name name-style="western"><surname>Guntin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cardinal</surname><given-names>KL</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K</given-names></name></person-group>. <article-title>Impact of Iliac Crest Bone Grafting on Postoperative Outcomes and Complication Rates Following Minimally Invasive Transforaminal Lumbar Interbody Fusion</article-title>. <source>Neurospine.</source><year>2019</year> Dec;<volume>16</volume>(<issue>4</issue>):<fpage>772</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">31284335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14245/ns.1938006.003</pub-id><pub-id pub-id-type="pmcid">PMC6944998</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="book"><article-title>Fortune Business Insights. Orthobiologics Market Size, Share &amp; Industry Analysis, By Product Type (Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Cellular Allograft, Allografts, and Others), By Application (Spinal Fusion, Maxillofacial &amp; Dental, Soft Tissue Repair, Reconstructive &amp; Fracture Surgery, and Others)</article-title>, <source>By End-user (Hospitals &amp; ASCs, Specialty Clinics, and Others), and Regional Forecast,</source>, <fpage>2024</fpage>-<lpage>2032</lpage>. <year>2024</year>. <comment>Accessed 2025 May 14. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173" ext-link-type="uri">https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173</ext-link></comment></mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadal&#224;</surname><given-names>G</given-names></name><name name-style="western"><surname>Ambrosio</surname><given-names>L</given-names></name><name name-style="western"><surname>De Salvatore</surname><given-names>S</given-names></name><name name-style="western"><surname>Riew</surname><given-names>DK</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Meisel</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Buser</surname><given-names>Z</given-names></name><name name-style="western"><surname>Denaro</surname><given-names>V</given-names></name></person-group>; <collab>AO Spine Knowledge Forum Degenerative</collab>. <article-title>The Role of Osteobiologics in Augmenting Spine Fusion in Unplated Anterior Cervical Discectomy and Fusion Compared to Plated Constructs: A Systematic Review and Meta-analysis</article-title>. <source>Global Spine J.</source><year>2024</year> Feb;<volume>14</volume>(<issue>2_suppl</issue>)<comment>(suppl)</comment>:<fpage>43S</fpage>-<lpage>58S</lpage>.<pub-id pub-id-type="pmid">38421326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/21925682231156865</pub-id><pub-id pub-id-type="pmcid">PMC10913900</pub-id></mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakashima</surname><given-names>T</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>A</given-names></name><name name-style="western"><surname>Kii</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Todo</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonohata</surname><given-names>M</given-names></name><name name-style="western"><surname>Mawatari</surname><given-names>M</given-names></name></person-group>. <article-title>Osteoconductivity and neurotoxicity of silver-containing hydroxyapatite coating cage for spinal interbody fusion in rats</article-title>. <source>JOR Spine.</source><year>2022</year> Nov 29;<volume>6</volume>(<issue>1</issue>):<fpage>e1236</fpage>.<pub-id pub-id-type="pmid">36994462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsp2.1236</pub-id><pub-id pub-id-type="pmcid">PMC10041372</pub-id></mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>MS</given-names></name><name name-style="western"><surname>Moon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JK</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>WY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HG</given-names></name></person-group>. <article-title>Platelet-rich plasma for the spinal fusion</article-title>. <source>J Orthop Surg (Hong Kong).</source><year>2018</year> Jan-Apr;<volume>26</volume>(<issue>1</issue>):<fpage>2309499018755772</fpage>.<pub-id pub-id-type="pmid">29415616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2309499018755772</pub-id></mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadomski</surname><given-names>BC</given-names></name><name name-style="western"><surname>Labus</surname><given-names>KM</given-names></name><name name-style="western"><surname>Puttlitz</surname><given-names>CM</given-names></name><name name-style="western"><surname>McGilvray</surname><given-names>KC</given-names></name><name name-style="western"><surname>Regan</surname><given-names>DP</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>B</given-names></name><name name-style="western"><surname>Seim</surname><given-names>HB</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Easley</surname><given-names>JT</given-names></name></person-group>. <article-title>Evaluation of lumbar spinal fusion utilizing recombinant human platelet derived growth factor-B chain homodimer (rhPDGF-BB) combined with a bovine collagen/&#946;-tricalcium phosphate (&#946;-TCP) matrix in an ovine model</article-title>. <source>JOR Spine.</source><year>2021</year> Jul 2;<volume>4</volume>(<issue>3</issue>):<fpage>e1166</fpage>.<pub-id pub-id-type="pmid">34611589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsp2.1166</pub-id><pub-id pub-id-type="pmcid">PMC8479519</pub-id></mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>KE</given-names></name><name name-style="western"><surname>Mesregah</surname><given-names>MK</given-names></name><name name-style="western"><surname>Fresquez</surname><given-names>Z</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>EW</given-names></name><name name-style="western"><surname>Buser</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name></person-group>. <article-title>Use of graft materials and biologics in spine deformity surgery: a state-of-the-art review</article-title>. <source>Spine Deform.</source><year>2022</year> Nov;<volume>10</volume>(<issue>6</issue>):<fpage>1217</fpage>-<lpage>31</lpage>.<pub-id pub-id-type="pmid">35733056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43390-022-00529-1</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paraj&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Alimi</surname><given-names>M</given-names></name><name name-style="western"><surname>Navarro-Ramirez</surname><given-names>R</given-names></name><name name-style="western"><surname>Christos</surname><given-names>P</given-names></name><name name-style="western"><surname>Torres-Campa</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lang</surname><given-names>G</given-names></name><name name-style="western"><surname>H&#228;rtl</surname><given-names>R</given-names></name></person-group>. <article-title>Minimally Invasive Transforaminal Lumbar Interbody Fusion: Meta-analysis of the Fusion Rates. What is the Optimal Graft Material?</article-title><source>Neurosurgery.</source><year>2017</year> Dec 1;<volume>81</volume>(<issue>6</issue>):<fpage>958</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">28419312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuros/nyx141</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tavares</surname><given-names>WM</given-names></name><name name-style="western"><surname>de Fran&#231;a</surname><given-names>SA</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>WS</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>MJ</given-names></name></person-group>. <article-title>A systematic review and meta-analysis of fusion rate enhancements and bone graft options for spine surgery</article-title>. <source>Sci Rep.</source><year>2022</year> May 9;<volume>12</volume>(<issue>1</issue>):<fpage>7546</fpage>.<pub-id pub-id-type="pmid">35534520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-11551-8</pub-id><pub-id pub-id-type="pmcid">PMC9085837</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>J</given-names></name><name name-style="western"><surname>Grimshaw</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Lalu</surname><given-names>MM</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Loder</surname><given-names>EW</given-names></name><name name-style="western"><surname>Mayo-Wilson</surname><given-names>E</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>S</given-names></name><name name-style="western"><surname>McGuinness</surname><given-names>LA</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name><name name-style="western"><surname>Tricco</surname><given-names>AC</given-names></name><name name-style="western"><surname>Welch</surname><given-names>VA</given-names></name><name name-style="western"><surname>Whiting</surname><given-names>P</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name></person-group>. <article-title>PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews</article-title>. <source>BMJ.</source><year>2021</year> Mar 29;<volume>372</volume>:<fpage>n160</fpage>.<pub-id pub-id-type="pmid">33781993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n160</pub-id><pub-id pub-id-type="pmcid">PMC8005925</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutton</surname><given-names>B</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>DM</given-names></name><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name><name name-style="western"><surname>Straus</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>JP</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>C</given-names></name><name name-style="western"><surname>Catal&#225;-L&#243;pez</surname><given-names>F</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><name name-style="western"><surname>Dickersin</surname><given-names>K</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name></person-group>. <article-title>The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations</article-title>. <source>Ann Intern Med.</source><year>2015</year> Jun 2;<volume>162</volume>(<issue>11</issue>):<fpage>777</fpage>-<lpage>84</lpage>.<pub-id pub-id-type="pmid">26030634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M14-2385</pub-id></mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>JAC</given-names></name><name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>RG</given-names></name><name name-style="western"><surname>Blencowe</surname><given-names>NS</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Cates</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>HY</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>MS</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>SM</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hopewell</surname><given-names>S</given-names></name><name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Junqueira</surname><given-names>DR</given-names></name><name name-style="western"><surname>J&#252;ni</surname><given-names>P</given-names></name><name name-style="western"><surname>Kirkham</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lasserson</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>McAleenan</surname><given-names>A</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>BC</given-names></name><name name-style="western"><surname>Shepperd</surname><given-names>S</given-names></name><name name-style="western"><surname>Shrier</surname><given-names>I</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name><name name-style="western"><surname>Tilling</surname><given-names>K</given-names></name><name name-style="western"><surname>White</surname><given-names>IR</given-names></name><name name-style="western"><surname>Whiting</surname><given-names>PF</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name></person-group>. <article-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</article-title>. <source>BMJ.</source><year>2019</year> Aug 28;<volume>366</volume>:<fpage>l4898</fpage>.<pub-id pub-id-type="pmid">31462531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l4898</pub-id></mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Del Giovane</surname><given-names>C</given-names></name><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>DM</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name></person-group>. <article-title>Evaluating the quality of evidence from a network meta-analysis</article-title>. <source>PLoS One.</source><year>2014</year> Jul 3;<volume>9</volume>(<issue>7</issue>):<fpage>e99682</fpage>.<pub-id pub-id-type="pmid">24992266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0099682</pub-id><pub-id pub-id-type="pmcid">PMC4084629</pub-id></mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balduzzi</surname><given-names>S</given-names></name><name name-style="western"><surname>R&#252;cker</surname><given-names>G</given-names></name><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Papakonstantinou</surname><given-names>T</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>O</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>G</given-names></name></person-group>. <article-title>netmeta: An R Package for Network Meta-Analysis Using Frequentist Methods</article-title>. <source>J Stat Softw.</source><year>2023</year>;<volume>106</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>R&#252;cker</surname><given-names>G</given-names></name></person-group>. <article-title>Network meta-analysis: application and practice using R software</article-title>. <source>Epidemiol Health.</source><year>2019</year>;<volume>41</volume>:<fpage>e2019013</fpage>.<pub-id pub-id-type="pmid">30999733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4178/epih.e2019013</pub-id><pub-id pub-id-type="pmcid">PMC6635665</pub-id></mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou-Madawi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ali</surname><given-names>SH</given-names></name><name name-style="western"><surname>Abdelmonem</surname><given-names>AM</given-names></name></person-group>. <article-title>Local Autograft Versus Iliac Crest Bone Graft PSF-Augmented TLIF in Low-Grade Isthmic and Degenerative Lumbar Spondylolisthesis</article-title>. <source>Global Spine J.</source><year>2022</year> Jan;<volume>12</volume>(<issue>1</issue>):<fpage>70</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">32914652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2192568220946319</pub-id><pub-id pub-id-type="pmcid">PMC8965310</pub-id></mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andresen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>S</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M&#216;</given-names></name></person-group>. <article-title>Safety and Reoperation Rates in Non-instrumented Lumbar Fusion Surgery: Secondary Report From a Randomized Controlled Trial of ABM/P-15 vs Allograft With Minimum 5 years Follow-Up</article-title>. <source>Global Spine J.</source><year>2024</year> Jan;<volume>14</volume>(<issue>1</issue>):<fpage>33</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">35481422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/21925682221090924</pub-id><pub-id pub-id-type="pmcid">PMC10676187</pub-id></mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name><name name-style="western"><surname>Transfeldt</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kitchel</surname><given-names>SH</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>RG</given-names></name><name name-style="western"><surname>Balderston</surname><given-names>RA</given-names></name></person-group>. <article-title>Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2</article-title>. <source>Spine (Phila Pa 1976).</source><year>2002</year> Nov 1;<volume>27</volume>(<issue>21</issue>):<fpage>2396</fpage>-<lpage>408</lpage>.<pub-id pub-id-type="pmid">12438990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007632-200211010-00015</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name><name name-style="western"><surname>Gornet</surname><given-names>MF</given-names></name><name name-style="western"><surname>Dickman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Zdeblick</surname><given-names>TA</given-names></name></person-group>. <article-title>Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages</article-title>. <source>J Spinal Disord Tech.</source><year>2002</year> Oct;<volume>15</volume>(<issue>5</issue>):<fpage>337</fpage>-<lpage>49</lpage>.<pub-id pub-id-type="pmid">12394656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00024720-200210000-00001</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>HS</given-names></name><name name-style="western"><surname>Gornet</surname><given-names>MF</given-names></name><name name-style="western"><surname>Longley</surname><given-names>MC</given-names></name></person-group>. <article-title>Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery</article-title>. <source>J Bone Joint Surg Am.</source><year>2005</year> Jun;<volume>87</volume>(<issue>6</issue>):<fpage>1205</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">15930528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.D.02532</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Rauschmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Fleege</surname><given-names>C</given-names></name><name name-style="western"><surname>Arabmotlagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name><name name-style="western"><surname>Martin</surname><given-names>K</given-names></name><name name-style="western"><surname>Rickert</surname><given-names>M</given-names></name></person-group>. <article-title>A Prospective, Randomized Study Evaluating Clinical and Radiographic Efficacy of Lumbar Interbody Fusion Performed Using a Truss Technology-Based Interbody Fusion Device With Homologous Bone or Bone Marrow Aspirate</article-title>. <source>Int J Spine Surg.</source><year>2020</year> Dec;<volume>14</volume>(<issue>6</issue>):<fpage>924</fpage>-<lpage>35</lpage>.<pub-id pub-id-type="pmid">33560252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14444/7141</pub-id><pub-id pub-id-type="pmcid">PMC7872402</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>M</given-names></name><name name-style="western"><surname>You</surname><given-names>KH</given-names></name><name name-style="western"><surname>Yeom</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KB</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Mid-term efficacy and safety of Escherichia coli-derived rhBMP-2/hydroxyapatite carrier in lumbar posterolateral fusion: a randomized, multicenter study</article-title>. <source>Eur Spine J.</source><year>2023</year> Jan;<volume>32</volume>(<issue>1</issue>):<fpage>353</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="pmid">36394652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-022-07440-3</pub-id></mixed-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubota</surname><given-names>G</given-names></name><name name-style="western"><surname>Kamoda</surname><given-names>H</given-names></name><name name-style="western"><surname>Orita</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakuma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inage</surname><given-names>K</given-names></name><name name-style="western"><surname>Sainoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>J</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>J</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohtori</surname><given-names>S</given-names></name></person-group>. <article-title>Platelet-rich plasma enhances bone union in posterolateral lumbar fusion: A prospective randomized controlled trial</article-title>. <source>Spine J.</source><year>2019</year> Feb;<volume>19</volume>(<issue>2</issue>):<fpage>e34</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">28735763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2017.07.167</pub-id></mixed-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coughlan</surname><given-names>M</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name><name name-style="western"><surname>Mostert</surname><given-names>AK</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>D</given-names></name><name name-style="western"><surname>Willems</surname><given-names>PC</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>G</given-names></name><name name-style="western"><surname>Ferch</surname><given-names>R</given-names></name></person-group>. <article-title>A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders</article-title>. <source>Spine (Phila Pa 1976).</source><year>2018</year> Aug 1;<volume>43</volume>(<issue>15</issue>):<fpage>E860</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">29652784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000002678</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>LY</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>LS</given-names></name></person-group>. <article-title>Single-level instrumented posterolateral fusion of lumbar spine with &#946;-tricalcium phosphate versus autograft: a prospective, randomized study with 3-year follow-up</article-title>. <source>Spine (Phila Pa 1976).</source><year>2008</year> May 20;<volume>33</volume>(<issue>12</issue>):<fpage>1299</fpage>-<lpage>304</lpage>.<pub-id pub-id-type="pmid">18496340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0b013e3181732a8e</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawson</surname><given-names>E</given-names></name><name name-style="western"><surname>Bae</surname><given-names>HW</given-names></name><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name><name name-style="western"><surname>Stambough</surname><given-names>JL</given-names></name><name name-style="western"><surname>Glassman</surname><given-names>SD</given-names></name></person-group>. <article-title>Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial</article-title>. <source>J Bone Joint Surg Am.</source><year>2009</year> Jul;<volume>91</volume>(<issue>7</issue>):<fpage>1604</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="pmid">19571082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.G.01157</pub-id></mixed-citation></ref><ref id="bib32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delawi</surname><given-names>D</given-names></name><name name-style="western"><surname>Dhert</surname><given-names>WJA</given-names></name><name name-style="western"><surname>Rillardon</surname><given-names>L</given-names></name><name name-style="western"><surname>Gay</surname><given-names>E</given-names></name><name name-style="western"><surname>Prestamburgo</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia-Fernandez</surname><given-names>C</given-names></name><name name-style="western"><surname>Guerado</surname><given-names>E</given-names></name><name name-style="western"><surname>Specchia</surname><given-names>N</given-names></name><name name-style="western"><surname>Van Susante</surname><given-names>JL</given-names></name><name name-style="western"><surname>Verschoor</surname><given-names>N</given-names></name><name name-style="western"><surname>van Ufford</surname><given-names>HM</given-names></name><name name-style="western"><surname>Oner</surname><given-names>FC</given-names></name></person-group>. <article-title>A prospective, randomized, controlled, multicenter study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety and feasibility</article-title>. <source>Spine (Phila Pa 1976).</source><year>2010</year> May 20;<volume>35</volume>(<issue>12</issue>):<fpage>1185</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="pmid">20445470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0b013e3181d3cf28</pub-id></mixed-citation></ref><ref id="bib33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delawi</surname><given-names>D</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>W</given-names></name><name name-style="western"><surname>van Susante</surname><given-names>JLC</given-names></name><name name-style="western"><surname>Rillardon</surname><given-names>L</given-names></name><name name-style="western"><surname>Prestamburgo</surname><given-names>D</given-names></name><name name-style="western"><surname>Specchia</surname><given-names>N</given-names></name><name name-style="western"><surname>Gay</surname><given-names>E</given-names></name><name name-style="western"><surname>Verschoor</surname><given-names>N</given-names></name><name name-style="western"><surname>Garcia-Fernandez</surname><given-names>C</given-names></name><name name-style="western"><surname>Guerado</surname><given-names>E</given-names></name><name name-style="western"><surname>Quarles van Ufford</surname><given-names>H</given-names></name><name name-style="western"><surname>Kruyt</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dhert</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Oner</surname><given-names>FC</given-names></name></person-group>. <article-title>OP-1 Compared with Iliac Crest Autograft in Instrumented Posterolateral Fusion: A Randomized, Multicenter Non-Inferiority Trial</article-title>. <source>J Bone Joint Surg Am.</source><year>2016</year> Mar 16;<volume>98</volume>(<issue>6</issue>):<fpage>441</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">26984911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.O.00209</pub-id></mixed-citation></ref><ref id="bib34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimar</surname><given-names>JR</given-names></name><name name-style="western"><surname>Glassman</surname><given-names>SD</given-names></name><name name-style="western"><surname>Burkus</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name></person-group>. <article-title>Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft</article-title>. <source>Spine (Phila Pa 1976).</source><year>2006</year> Oct 15;<volume>31</volume>(<issue>22</issue>):<fpage>2534</fpage>-<lpage>9</lpage><comment>, discussion 2540</comment>.<pub-id pub-id-type="pmid">17047540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.brs.0000240715.78657.81</pub-id></mixed-citation></ref><ref id="bib35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimar</surname><given-names>JR</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Glassman</surname><given-names>SD</given-names></name><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name><name name-style="western"><surname>Pryor</surname><given-names>PW</given-names></name><name name-style="western"><surname>Hardacker</surname><given-names>JW</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name></person-group>. <article-title>Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis</article-title>. <source>J Bone Joint Surg Am.</source><year>2009</year> Jun;<volume>91</volume>(<issue>6</issue>):<fpage>1377</fpage>-<lpage>86</lpage>.<pub-id pub-id-type="pmid">19487515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.H.00200</pub-id></mixed-citation></ref><ref id="bib36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a de Frutos</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Tarti&#232;re</surname><given-names>P</given-names></name><name name-style="western"><surname>Coll</surname><given-names>Bonet R</given-names></name><name name-style="western"><surname>Ubierna Garc&#233;s</surname><given-names>MT</given-names></name><name name-style="western"><surname>Del Arco Churruca</surname><given-names>A</given-names></name><name name-style="western"><surname>Rivas Garc&#237;a</surname><given-names>A</given-names></name><name name-style="western"><surname>Matamalas Adrover</surname><given-names>A</given-names></name><name name-style="western"><surname>Sal&#243; Bru</surname><given-names>G</given-names></name><name name-style="western"><surname>Velazquez</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Vila-Canet</surname><given-names>G</given-names></name><name name-style="western"><surname>Garc&#237;a-Lopez</surname><given-names>J</given-names></name><name name-style="western"><surname>Vives</surname><given-names>J</given-names></name><name name-style="western"><surname>Codinach</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L</given-names></name><name name-style="western"><surname>Bag&#243; Granell</surname><given-names>J</given-names></name><name name-style="western"><surname>C&#224;ceres Palou</surname><given-names>E</given-names></name></person-group>. <article-title>Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery</article-title>. <source>Spine J.</source><year>2020</year> Dec;<volume>20</volume>(<issue>12</issue>):<fpage>1899</fpage>-<lpage>910</lpage>.<pub-id pub-id-type="pmid">32730985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2020.07.014</pub-id></mixed-citation></ref><ref id="bib37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glassman</surname><given-names>SD</given-names></name><name name-style="western"><surname>Dimar</surname><given-names>JR</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Puno</surname><given-names>RM</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JR</given-names></name></person-group>. <article-title>Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion</article-title>. <source>Spine (Phila Pa 1976).</source><year>2005</year> Aug 1;<volume>30</volume>(<issue>15</issue>):<fpage>1694</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">16094268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.brs.0000172157.39513.80</pub-id></mixed-citation></ref><ref id="bib38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glassman</surname><given-names>SD</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name><name name-style="western"><surname>Djurasovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Puno</surname><given-names>RM</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JR</given-names></name><name name-style="western"><surname>Dimar</surname><given-names>JR</given-names></name></person-group>. <article-title>RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age</article-title>. <source>Spine (Phila Pa 1976).</source><year>2008</year> Dec 15;<volume>33</volume>(<issue>26</issue>):<fpage>2843</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">19092613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0b013e318190705d</pub-id></mixed-citation></ref><ref id="bib39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haid</surname><given-names>RW Jr</given-names></name><name name-style="western"><surname>Branch</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Alexander</surname><given-names>JT</given-names></name><name name-style="western"><surname>Burkus</surname><given-names>JK</given-names></name></person-group>. <article-title>Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages</article-title>. <source>Spine J.</source><year>2004</year> Sep-Oct;<volume>4</volume>(<issue>5</issue>):<fpage>527</fpage>-<lpage>38</lpage><comment>, discussion 538-9</comment>.<pub-id pub-id-type="pmid">15363423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2004.03.025</pub-id></mixed-citation></ref><ref id="bib40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>R</given-names></name><name name-style="western"><surname>Komz&#225;k</surname><given-names>M</given-names></name><name name-style="western"><surname>Ok&#225;l</surname><given-names>F</given-names></name><name name-style="western"><surname>N&#225;hl&#237;k</surname><given-names>D</given-names></name><name name-style="western"><surname>Jajtner</surname><given-names>P</given-names></name><name name-style="western"><surname>Puskeiler</surname><given-names>M</given-names></name></person-group>. <article-title>Allograft alone versus allograft with bone marrow concentrate for the healing of the instrumented posterolateral lumbar fusion</article-title>. <source>Spine J.</source><year>2014</year> Jul 1;<volume>14</volume>(<issue>7</issue>):<fpage>1318</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">24361998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2013.12.014</pub-id></mixed-citation></ref><ref id="bib41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurlbert</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>D</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>S</given-names></name><name name-style="western"><surname>Mahood</surname><given-names>J</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E</given-names></name><name name-style="western"><surname>McBroom</surname><given-names>R</given-names></name><name name-style="western"><surname>Jodoin</surname><given-names>A</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>C</given-names></name></person-group>. <article-title>rhBMP-2 for posterolateral instrumented lumbar fusion: a multicenter prospective randomized controlled trial</article-title>. <source>Spine (Phila Pa 1976).</source><year>2013</year> Dec 1;<volume>38</volume>(<issue>25</issue>):<fpage>2139</fpage>-<lpage>48</lpage>.<pub-id pub-id-type="pmid">24296479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000000007</pub-id></mixed-citation></ref><ref id="bib42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyun</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ha</surname><given-names>Y</given-names></name></person-group>. <article-title>A Prospective, Multi-Center, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of the Synthetic Bone Graft Material DBM Gel with rhBMP-2 versus DBM Gel Used during the TLIF Procedure in Patients with Lumbar Disc Disease</article-title>. <source>J Korean Neurosurg Soc.</source><year>2021</year> Jul;<volume>64</volume>(<issue>4</issue>):<fpage>562</fpage>-<lpage>74</lpage>.<pub-id pub-id-type="pmid">33906347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3340/jkns.2020.0331</pub-id><pub-id pub-id-type="pmcid">PMC8273782</pub-id></mixed-citation></ref><ref id="bib43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Andresen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jespersen</surname><given-names>AB</given-names></name><name name-style="western"><surname>St&#248;ttrup</surname><given-names>C</given-names></name><name name-style="western"><surname>Carreon</surname><given-names>LY</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>S</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M&#216;</given-names></name></person-group>. <article-title>Randomized double blind clinical trial of ABM/P-15 versus allograft in noninstrumented lumbar fusion surgery</article-title>. <source>Spine J.</source><year>2020</year> May;<volume>20</volume>(<issue>5</issue>):<fpage>677</fpage>-<lpage>84</lpage>.<pub-id pub-id-type="pmid">32001384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2020.01.009</pub-id></mixed-citation></ref><ref id="bib44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnsson</surname><given-names>R</given-names></name><name name-style="western"><surname>Str&#246;mqvist</surname><given-names>B</given-names></name><name name-style="western"><surname>Aspenberg</surname><given-names>P</given-names></name></person-group>. <article-title>Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies</article-title>. <source>Spine (Phila Pa 1976).</source><year>2002</year> Dec 1;<volume>27</volume>(<issue>23</issue>):<fpage>2654</fpage>-<lpage>61</lpage>.<pub-id pub-id-type="pmid">12461391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007632-200212010-00004</pub-id></mixed-citation></ref><ref id="bib45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>An</surname><given-names>H</given-names></name><name name-style="western"><surname>Hilibrand</surname><given-names>A</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>ST</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>E</given-names></name><name name-style="western"><surname>Boden</surname><given-names>S</given-names></name></person-group>. <article-title>Grafton and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions</article-title>. <source>Spine (Phila Pa 1976).</source><year>2012</year> May 20;<volume>37</volume>(<issue>12</issue>):<fpage>1083</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="pmid">22076647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0b013e31823ed817</pub-id></mixed-citation></ref><ref id="bib46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kong</surname><given-names>CB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Shim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Koo</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>BS</given-names></name></person-group>. <article-title>Comparison of fusion rate and clinical results between CaO-SiO<sub>2</sub>-P<sub>2</sub>O<sub>5</sub>-B<sub>2</sub>O<sub>3</sub> bioactive glass ceramics spacer with titanium cages in posterior lumbar interbody fusion</article-title>. <source>Spine J.</source><year>2016</year> Nov;<volume>16</volume>(<issue>11</issue>):<fpage>1367</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">27498334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2016.07.531</pub-id></mixed-citation></ref><ref id="bib47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Han</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>BS</given-names></name></person-group>. <article-title>A Long-Term Follow-up, Multicenter, Comparative Study of the Radiologic, and Clinical Results Between a CaO-SiO2-P2O5-B2O3 Bioactive Glass Ceramics (BGS-7) Intervertebral Spacer and Titanium Cage in 1-Level Posterior Lumbar Interbody Fusion</article-title>. <source>Clin Spine Surg.</source><year>2020</year> Aug;<volume>33</volume>(<issue>7</issue>):<fpage>E322</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">32080009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BSD.0000000000000950</pub-id><pub-id pub-id-type="pmcid">PMC7447185</pub-id></mixed-citation></ref><ref id="bib48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menezes</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>GC</given-names></name><name name-style="western"><surname>do Valle</surname><given-names>GSO</given-names></name><name name-style="western"><surname>de Oliveira Arruda</surname><given-names>A</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>EG</given-names></name></person-group>. <article-title>Ceramic bone graft substitute vs autograft in XLIF: a prospective randomized single-center evaluation of radiographic and clinical outcomes</article-title>. <source>Eur Spine J.</source><year>2022</year> Sep;<volume>31</volume>(<issue>9</issue>):<fpage>2262</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">35723748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-022-07275-y</pub-id><pub-id pub-id-type="pmcid">PMC9208346</pub-id></mixed-citation></ref><ref id="bib49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michielsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sys</surname><given-names>J</given-names></name><name name-style="western"><surname>Rigaux</surname><given-names>A</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>C</given-names></name></person-group>. <article-title>The effect of recombinant human bone morphogenetic protein-2 in single-level posterior lumbar interbody arthrodesis</article-title>. <source>J Bone Joint Surg Am.</source><year>2013</year> May 15;<volume>95</volume>(<issue>10</issue>):<fpage>873</fpage>-<lpage>80</lpage>.<pub-id pub-id-type="pmid">23677353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.L.00137</pub-id></mixed-citation></ref><ref id="bib50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohtori</surname><given-names>S</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Koshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Takaso</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>G</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Orita</surname><given-names>S</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ochiai</surname><given-names>N</given-names></name><name name-style="western"><surname>Kishida</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuniyoshi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>J</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Arai</surname><given-names>G</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamoda</surname><given-names>H</given-names></name><name name-style="western"><surname>Toyone</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K</given-names></name></person-group>. <article-title>Single-level instrumented posterolateral fusion of the lumbar spine with a local bone graft versus an iliac crest bone graft: a prospective, randomized study with a 2-year follow-up</article-title>. <source>Eur Spine J.</source><year>2011</year> Apr;<volume>20</volume>(<issue>4</issue>):<fpage>635</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">21165658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-010-1656-7</pub-id><pub-id pub-id-type="pmcid">PMC3065607</pub-id></mixed-citation></ref><ref id="bib51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimenta</surname><given-names>L</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>L</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>E</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>R</given-names></name></person-group>. <article-title>A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2</article-title>. <source>J Neurol Surg A Cent Eur Neurosurg.</source><year>2013</year> Nov;<volume>74</volume>(<issue>6</issue>):<fpage>343</fpage>-<lpage>50</lpage>.<pub-id pub-id-type="pmid">23444134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0032-1333420</pub-id></mixed-citation></ref><ref id="bib52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putzier</surname><given-names>M</given-names></name><name name-style="western"><surname>Strube</surname><given-names>P</given-names></name><name name-style="western"><surname>Funk</surname><given-names>J</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C</given-names></name><name name-style="western"><surname>Perka</surname><given-names>C</given-names></name></person-group>. <article-title>Periosteal cells compared with autologous cancellous bone in lumbar segmental fusion</article-title>. <source>J Neurosurg Spine.</source><year>2008</year> Jun;<volume>8</volume>(<issue>6</issue>):<fpage>536</fpage>-<lpage>43</lpage>.<pub-id pub-id-type="pmid">18518674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/SPI/2008/8/6/536</pub-id></mixed-citation></ref><ref id="bib53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putzier</surname><given-names>M</given-names></name><name name-style="western"><surname>Strube</surname><given-names>P</given-names></name><name name-style="western"><surname>Funk</surname><given-names>JF</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#246;nig</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Perka</surname><given-names>C</given-names></name><name name-style="western"><surname>Pruss</surname><given-names>A</given-names></name></person-group>. <article-title>Allogenic versus autologous cancellous bone in lumbar segmental spondylodesis: a randomized prospective study</article-title>. <source>Eur Spine J.</source><year>2009</year> May;<volume>18</volume>(<issue>5</issue>):<fpage>687</fpage>-<lpage>95</lpage>.<pub-id pub-id-type="pmid">19148687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-008-0875-7</pub-id><pub-id pub-id-type="pmcid">PMC3234005</pub-id></mixed-citation></ref><ref id="bib54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickert</surname><given-names>M</given-names></name><name name-style="western"><surname>Fleege</surname><given-names>C</given-names></name><name name-style="western"><surname>Papachristos</surname><given-names>I</given-names></name><name name-style="western"><surname>Makowski</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rauschmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Arabmotlagh</surname><given-names>M</given-names></name></person-group>. <article-title>Clinical Outcome After Anterior Lumbar Interbody Fusion With a New Osteoinductive Bone Substitute Material: A Randomized Clinical Pilot Study</article-title>. <source>Clin Spine Surg.</source><year>2019</year> Aug;<volume>32</volume>(<issue>7</issue>):<fpage>E319</fpage>-<lpage>25</lpage>.<pub-id pub-id-type="pmid">30730430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BSD.0000000000000802</pub-id></mixed-citation></ref><ref id="bib55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasso</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kitchel</surname><given-names>SH</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>EGA</given-names></name></person-group>. <article-title>A prospective, randomized controlled clinical trial of anterior lumbar interbody fusion using a titanium cylindrical threaded fusion device</article-title>. <source>Spine (Phila Pa 1976).</source><year>2004</year> Jan 15;<volume>29</volume>(<issue>2</issue>):<fpage>113</fpage>-<lpage>22</lpage><comment>, discussion 121-2</comment>.<pub-id pub-id-type="pmid">14722400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.BRS.0000107007.31714.77</pub-id></mixed-citation></ref><ref id="bib56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sys</surname><given-names>J</given-names></name><name name-style="western"><surname>Weyler</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Der Zijden</surname><given-names>T</given-names></name><name name-style="western"><surname>Parizel</surname><given-names>P</given-names></name><name name-style="western"><surname>Michielsen</surname><given-names>J</given-names></name></person-group>. <article-title>Platelet-rich plasma in mono-segmental posterior lumbar interbody fusion</article-title>. <source>Eur Spine J.</source><year>2011</year> Oct;<volume>20</volume>(<issue>10</issue>):<fpage>1650</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">21744284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-011-1897-0</pub-id><pub-id pub-id-type="pmcid">PMC3175872</pub-id></mixed-citation></ref><ref id="bib57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccaro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Fischgrund</surname><given-names>J</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Truumees</surname><given-names>E</given-names></name><name name-style="western"><surname>Herkowitz</surname><given-names>HN</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>F</given-names></name><name name-style="western"><surname>Hilibrand</surname><given-names>A</given-names></name><name name-style="western"><surname>Albert</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>T</given-names></name><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name></person-group>. <article-title>A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis</article-title>. <source>Spine (Phila Pa 1976).</source><year>2004</year> Sep 1;<volume>29</volume>(<issue>17</issue>):<fpage>1885</fpage>-<lpage>92</lpage>.<pub-id pub-id-type="pmid">15534410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.brs.0000137062.79201.98</pub-id></mixed-citation></ref><ref id="bib58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccaro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Fischgrund</surname><given-names>J</given-names></name><name name-style="western"><surname>Truumees</surname><given-names>E</given-names></name><name name-style="western"><surname>Herkowitz</surname><given-names>HN</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>F</given-names></name><name name-style="western"><surname>Hilibrand</surname><given-names>A</given-names></name><name name-style="western"><surname>Albert</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>T</given-names></name><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name></person-group>. <article-title>Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study</article-title>. <source>Spine (Phila Pa 1976).</source><year>2005</year> Dec 15;<volume>30</volume>(<issue>24</issue>):<fpage>2709</fpage>-<lpage>16</lpage>.<pub-id pub-id-type="pmid">16371892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.brs.0000190812.08447.ba</pub-id></mixed-citation></ref><ref id="bib59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccaro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Whang</surname><given-names>PG</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>FM</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Albert</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hilibrand</surname><given-names>AS</given-names></name><name name-style="western"><surname>Brower</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kurd</surname><given-names>MF</given-names></name><name name-style="western"><surname>Appannagari</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Fischgrund</surname><given-names>JS</given-names></name></person-group>. <article-title>The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study</article-title>. <source>Spine J.</source><year>2008</year> May-Jun;<volume>8</volume>(<issue>3</issue>):<fpage>457</fpage>-<lpage>65</lpage>.<pub-id pub-id-type="pmid">17588821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2007.03.012</pub-id></mixed-citation></ref><ref id="bib60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccaro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>JP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Katz</surname><given-names>LD</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Fischgrund</surname><given-names>JS</given-names></name><name name-style="western"><surname>Krop</surname><given-names>J</given-names></name><name name-style="western"><surname>Fehlings</surname><given-names>MG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D</given-names></name></person-group>. <article-title>The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (&gt;4 years) pivotal study</article-title>. <source>Spine (Phila Pa 1976).</source><year>2008</year> Dec 15;<volume>33</volume>(<issue>26</issue>):<fpage>2850</fpage>-<lpage>62</lpage>.<pub-id pub-id-type="pmid">19092614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0b013e31818a314d</pub-id></mixed-citation></ref><ref id="bib61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villavicencio</surname><given-names>AT</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>EL</given-names></name><name name-style="western"><surname>Rajpal</surname><given-names>S</given-names></name><name name-style="western"><surname>Beasley</surname><given-names>K</given-names></name><name name-style="western"><surname>Burneikiene</surname><given-names>S</given-names></name></person-group>. <article-title>Prospective, randomized, double-blinded clinical trial comparing PEEK and allograft spacers in patients undergoing transforaminal lumbar interbody fusion surgeries</article-title>. <source>Spine J.</source><year>2022</year> Jan;<volume>22</volume>(<issue>1</issue>):<fpage>84</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="pmid">34116214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spinee.2021.06.005</pub-id></mixed-citation></ref><ref id="bib62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>vonderHoeh</surname><given-names>NH</given-names></name><name name-style="western"><surname>Voelker</surname><given-names>A</given-names></name><name name-style="western"><surname>Heyde</surname><given-names>CE</given-names></name></person-group>. <article-title>Results of lumbar spondylodeses using different bone grafting materials after transforaminal lumbar interbody fusion (TLIF)</article-title>. <source>Eur Spine J.</source><year>2017</year> Nov;<volume>26</volume>(<issue>11</issue>):<fpage>2835</fpage>-<lpage>42</lpage>.<pub-id pub-id-type="pmid">28547573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-017-5145-0</pub-id></mixed-citation></ref><ref id="bib63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohi</surname><given-names>El din M</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tareef</surname><given-names>TA</given-names></name><name name-style="western"><surname>Baraka</surname><given-names>M</given-names></name><name name-style="western"><surname>Gabr</surname><given-names>M</given-names></name><name name-style="western"><surname>Omar</surname><given-names>AH</given-names></name></person-group>. <article-title>Platelet Concentrate In Lumbar Interbody Cage Fusion: A New Era of Modality Of Fusion</article-title>. <source>Open Access Macedonian Journal of Medical Sciences.</source><year>2021</year>;<volume>9</volume>(<issue>B</issue>):<fpage>356</fpage>-<lpage>62</lpage>.</mixed-citation></ref><ref id="bib64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>ST</given-names></name><name name-style="western"><surname>Brodke</surname><given-names>DS</given-names></name><name name-style="western"><surname>Park</surname><given-names>JB</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>P</given-names></name><name name-style="western"><surname>Meisel</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Buser</surname><given-names>Z</given-names></name></person-group>. <article-title>Development of AOSpine BOnE (Bone Osteobiologics and Evidence) Classification</article-title>. <source>Global Spine J.</source><year>2020</year> Oct;<volume>10</volume>(<issue>7</issue>):<fpage>871</fpage>-<lpage>4</lpage>.<pub-id pub-id-type="pmid">32905732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2192568219880176</pub-id><pub-id pub-id-type="pmcid">PMC7485069</pub-id></mixed-citation></ref><ref id="bib65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meisel</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Martin</surname><given-names>CT</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>JP</given-names></name><name name-style="western"><surname>Muthu</surname><given-names>S</given-names></name><name name-style="western"><surname>Hamouda</surname><given-names>WO</given-names></name><name name-style="western"><surname>Rodrigues-Pinto</surname><given-names>R</given-names></name><name name-style="western"><surname>Arts</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Viswanadha</surname><given-names>AK</given-names></name><name name-style="western"><surname>Vadal&#224;</surname><given-names>G</given-names></name><name name-style="western"><surname>Vergroesen</surname><given-names>PA</given-names></name><name name-style="western"><surname>&#262;orluka</surname><given-names>S</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Demetriades</surname><given-names>AK</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Riew</surname><given-names>KD</given-names></name><name name-style="western"><surname>Papavero</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>S</given-names></name><name name-style="western"><surname>Fekete</surname><given-names>T</given-names></name><name name-style="western"><surname>Uz Zaman</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Sharkawi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>D</given-names></name><name name-style="western"><surname>Cho</surname><given-names>SK</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>T</given-names></name><name name-style="western"><surname>Santesso</surname><given-names>N</given-names></name><name name-style="western"><surname>Buser</surname><given-names>Z</given-names></name></person-group>. <article-title>AO Spine Guideline for the Use of Osteobiologics (AOGO) in Anterior Cervical Discectomy and Fusion for Spinal Degenerative Cases</article-title>. <source>Global Spine J.</source><year>2024</year> Feb;<volume>14</volume>(<issue>2_suppl</issue>)<comment>(suppl)</comment>:<fpage>6S</fpage>-<lpage>13S</lpage>.<pub-id pub-id-type="pmid">38421322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/21925682231178204</pub-id><pub-id pub-id-type="pmcid">PMC10913909</pub-id></mixed-citation></ref><ref id="bib66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>AW</given-names></name><name name-style="western"><surname>LaChaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Asatrian</surname><given-names>G</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ting</surname><given-names>K</given-names></name><name name-style="western"><surname>Soo</surname><given-names>C</given-names></name></person-group>. <article-title>A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2</article-title>. <source>Tissue Eng Part B Rev.</source><year>2016</year> Aug;<volume>22</volume>(<issue>4</issue>):<fpage>284</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="pmid">26857241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ten.teb.2015.0357</pub-id><pub-id pub-id-type="pmcid">PMC4964756</pub-id></mixed-citation></ref><ref id="bib67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>NE</given-names></name><name name-style="western"><surname>Schwall</surname><given-names>GS</given-names></name></person-group>. <article-title>Costs and frequency of &#8220;off-label&#8221; use of INFUSE for spinal fusions at one institution in 2010</article-title>. <source>Surg Neurol Int.</source><year>2011</year>;<volume>2</volume>(<issue>1</issue>):<fpage>115</fpage>.<pub-id pub-id-type="pmid">21886888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2152-7806.83929</pub-id><pub-id pub-id-type="pmcid">PMC3162796</pub-id></mixed-citation></ref><ref id="bib68"><label>68</label><mixed-citation publication-type="webpage"><article-title>Cerapedics. i-FACTOR Putty &#8211; eIFU</article-title>. <comment>Accessed 2025 May 14. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cerapedics.com/IFU-900" ext-link-type="uri">https://www.cerapedics.com/IFU-900</ext-link></comment></mixed-citation></ref><ref id="bib69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#233;bert</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E</given-names></name><name name-style="western"><surname>Wedderkopp</surname><given-names>N</given-names></name><name name-style="western"><surname>Bigney</surname><given-names>E</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>E</given-names></name><name name-style="western"><surname>Darling</surname><given-names>M</given-names></name><name name-style="western"><surname>Hall</surname><given-names>H</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>CG</given-names></name><name name-style="western"><surname>Rampersaud</surname><given-names>YR</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>KC</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>WB</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Paquet</surname><given-names>J</given-names></name><name name-style="western"><surname>Attabib</surname><given-names>N</given-names></name><name name-style="western"><surname>Jarzem</surname><given-names>P</given-names></name><name name-style="western"><surname>Wai</surname><given-names>EK</given-names></name><name name-style="western"><surname>Rasoulinejad</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>H</given-names></name><name name-style="western"><surname>Nataraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>A</given-names></name><name name-style="western"><surname>Manson</surname><given-names>N</given-names></name></person-group>. <article-title>Preoperative Factors Predict Postoperative Trajectories of Pain and Disability Following Surgery for Degenerative Lumbar Spinal Stenosis</article-title>. <source>Spine (Phila Pa 1976).</source><year>2020</year> Nov 1;<volume>45</volume>(<issue>21</issue>):<fpage>E1421</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">32541610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000003587</pub-id><pub-id pub-id-type="pmcid">PMC7547903</pub-id></mixed-citation></ref><ref id="bib70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name></person-group>. <article-title>A meta analysis of lumbar spinal fusion surgery using bone morphogenetic proteins and autologous iliac crest bone graft</article-title>. <source>PLoS One.</source><year>2014</year> Jun 2;<volume>9</volume>(<issue>6</issue>):<fpage>e97049</fpage>.<pub-id pub-id-type="pmid">24886911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0097049</pub-id><pub-id pub-id-type="pmcid">PMC4041715</pub-id></mixed-citation></ref><ref id="bib71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>JT</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>YC</given-names></name></person-group>. <article-title>Efficacy and safety of bone substitutes in lumbar spinal fusion: a systematic review and network meta-analysis of randomized controlled trials</article-title>. <source>Eur Spine J.</source><year>2020</year> Jun;<volume>29</volume>(<issue>6</issue>):<fpage>1261</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">31872300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-019-06257-x</pub-id></mixed-citation></ref><ref id="bib72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>RP</given-names></name><name name-style="western"><surname>Nordberg</surname><given-names>RC</given-names></name><name name-style="western"><surname>Hu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Currall</surname><given-names>SC</given-names></name><name name-style="western"><surname>Athanasiou</surname><given-names>KA</given-names></name></person-group>. <article-title>Commercialization of regenerative-medicine therapies</article-title>. <source>Nature Reviews Bioengineering.</source><year>2023</year>;<volume>1</volume>(<issue>12</issue>):<fpage>906</fpage>-<lpage>29</lpage>.</mixed-citation></ref><ref id="bib73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schol</surname><given-names>J</given-names></name><name name-style="western"><surname>Tamagawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Volleman</surname><given-names>TNE</given-names></name><name name-style="western"><surname>Ishijima</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>D</given-names></name></person-group>. <article-title>A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis</article-title>. <source>JOR Spine.</source><year>2024</year> Jun 24;<volume>7</volume>(<issue>2</issue>):<fpage>e1348</fpage>.<pub-id pub-id-type="pmid">38919468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsp2.1348</pub-id><pub-id pub-id-type="pmcid">PMC11196836</pub-id></mixed-citation></ref><ref id="bib74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>LI</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>F</given-names></name><name name-style="western"><surname>Rodriguez-Granrose</surname><given-names>D</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>K</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>LH</given-names></name><name name-style="western"><surname>Foley</surname><given-names>KT</given-names></name></person-group>. <article-title>Identifying and Managing Sources of Variability in Cell Therapy Manufacturing and Clinical Trials</article-title>. <source>Regenerative Engineering and Translational Medicine.</source><year>2019</year>;<volume>5</volume>(<issue>4</issue>):<fpage>354</fpage>-<lpage>61</lpage>.</mixed-citation></ref><ref id="bib75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salamanna</surname><given-names>F</given-names></name><name name-style="western"><surname>Contartese</surname><given-names>D</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>G</given-names></name><name name-style="western"><surname>Ruffilli</surname><given-names>A</given-names></name><name name-style="western"><surname>Manzetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Viroli</surname><given-names>G</given-names></name><name name-style="western"><surname>Traversari</surname><given-names>M</given-names></name><name name-style="western"><surname>Faldini</surname><given-names>C</given-names></name><name name-style="western"><surname>Giavaresi</surname><given-names>G</given-names></name></person-group>. <article-title>Efficacy of using autologous cells with graft substitutes for spinal fusion surgery: A systematic review and meta-analysis of clinical outcomes and imaging features</article-title>. <source>JOR Spine.</source><year>2024</year> Jun 28;<volume>7</volume>(<issue>3</issue>):<fpage>e1347</fpage>.<pub-id pub-id-type="pmid">38947860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsp2.1347</pub-id><pub-id pub-id-type="pmcid">PMC11212337</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>